

Notes

Chapitre I

1. R. Kurzweil, 2005, *The Singularity Is Near : When Humans Transcend Biology*, New York, Viking Press.
2. R.N. Anderson, 2002, *National Vital Statistics Report*, 2002;50:16: 1–86.
3. J.C. Riley, 2001, *Rising Life Expectancy: A Global History*, Cambridge, Cambridge University Press.
4. F. Fukuyama, 2002, *Our Posthuman Future: Consequences of the Biotechnology Revolution*, New York, Farrar Straus.
5. O.W. Rasmussen *et al.*, 1993, « Effects on blood pressure, glucose and lipid levels of a highmonounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects », *Diabetes Care*, 16:1565–1571.
6. D. Ornish, 1990, « Can lifestyle changes reverse coronary heart disease? », *Lancet*, 336: 129–133.
7. E.G. Vermeulen *et al.*, 2000, « Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of sub clinical atherosclerosis: a randomized, placebo-controlled trial », *Lancet*, 12; 355(9203): 517–522.
8. L.A. Ries *et al.*, eds, *SEER Cancer Statistics Review, 1973–1999*, National Cancer Institute, Bethesda, Maryland. J.M. Ferrante *et al.*, 2000, « Clinical and Demographic Predictors of Late-Stage Cervical Cancer », *Arch Fam Med*. 9: 439–445. A. Srikameswaran, 2002, « Experts discuss promising new test for ovarian cancer » *Pittsburgh Post-Gazette*, May 7.

Chapitre 2

1. E. Drexler and C. Peterson 1991, *Unbounding the Future: The Nanotechnology Revolution*. New York : William Morrow and Company.
2. E. Marshall, 1999 « An array of uses: expression patterns in strawberries, Ebola, TB, and mouse cells », *Science*, 286(5439): 445.
3. S. F. Gilbert, 2000, *Developmental Biology*, Sunderland, Massachusetts: Sinauer Associates.
4. A. Biroccio, C. Leonetti, and G. Zupi, 2003, « The future of antisense therapy : combination with anticancer treatments », *Oncogene*, 29;22(42): 6579–6588. Jiang *et al.*, 2003, « Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma », *J Orthop Res*, 21(6): 1063–1070.
5. J.C. Cheng, T B. Moore, K.M. Sakamoto, 2003 « RNA interference and human disease », *Mol Genet Metab*, 80(1–2): 121–128. L. Zhang, D.K. Fogg, D.M. Waisman, 2003, « RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells », *J Biol Chem*. 21.
6. K. Smith, 2002 « Gene transfer in higher animals: theoretical considerations and key concepts » *J Biotechnol*, 9;99(1): 1–22.
7. L. Wu, M. Johnson, M. Sato, 2003 « Transcriptionally targeted gene therapy to detect and treat cancer » *Trends Mol Med*, 9(10): 421–429.
8. A. E. Trezise *et al.*, 2003 « In vivo gene expression: DNA electrotransfer » *Curr Opin Mol Ther*, 5(4): 397–404.

SERONS-NOUS IMMORTELS ?

9. B. Dekel *et al.*, 2003 « Human and porcine early kidney precursors as a new source for transplantation », *Nature Med*, 1;(9): 53–60.
10. F. Xue *et al.*, 2002 « Aberrant patterns of X chromosome inactivation in bovine clones » *Nat Genet*, 31(2): 216–220.
11. J.B. Gurdon, A. Colman, 1999 « The future of cloning » *Nature*, 402: 743–746; G. Stock and J. Campbell, eds. 2000, *Engineering the Human Germline: An Exploration of the Science and Ethics of Altering the Genes We Pass to Our Children*, New York: Oxford University Press.
12. W.S. Hwang, 2004 « Evidence of a Pluripotent Human Embryonic Stem Cell Line Derived from a Cloned Blastocyst » *Science*, 12;303(5664): 1669–1674.
13. L. Yang *et al.*, 2002, « In vitro transdifferentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells », *Proc Natl Acad Sci USA*, 11;99(12): 8078–8083). Z. Qu-Petersen *et al.*, 2002 « Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration », *J Cell Biol*, 157: 851–864.
14. A.M. Hakelien *et al.*, 2002 « Reprogramming fibroblasts to express T-cell functions using cell extracts », *Nature Biotechnology*, 20: 460–466.
15. R.P. Lanza *et al.*, 2000 « Extension of cell life-span and telomere length in animals cloned from senescent somatic cells » *Science*, 28;288(5466): 665–669. J.C. Ameisen, 2002 « On the origin, evolution, and nature of programmed cell death: a timeline of four billion years », *Cell Death & Differentiation*, 9(4): 367–393.
16. A.D. de Grey, 2003 « The foreseeability of real anti-aging medicine: focusing the debate » *Exp Gerontol*, 38(9): 927–934. A.D. de Grey, 2003 « An engineer's approach to the development of real anti-aging medicine », *Sci SAGE KE*, 8. A.D. de Grey *et al.*, 2002 « Is human aging still mysterious enough to be left only to scientists », *Bioessays*, 24(7): 667–676.
17. A.D. de Grey *et al.* 2004, « Total deletion of in vivo telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers » *Annals NY Acad Sci*, 1019:147–170.
18. O.J. Finn, 2003, « Cancer vaccines: between the idea and the reality » *Nat Rev Immunol*, 3(8):630–641. R.C. Kennedy, M. H. Shearer, 2003 « A role for antibodies in tumor immunity » *Int Rev Immunol*, 22(2):141–172.
19. A.D. de Grey, 2002, « The reductive hotspot hypothesis of mammalian aging: membrane metabolism magnifies mutant mitochondrial mischief », *Eur J Biochem*, 269(8): 2003–2009. P.F. Chinnery *et al.*, 2002 « Accumulation of mitochondrial DNA mutations in ageing, cancer, and mitochondrial disease: is there a common mechanism? » *Lancet*, 26;360(9342):1323–1235. A.D. de Grey, 2000, « Mitochondrial gene therapy: an arena for the biomedical use of inteins », *Trends Biotechnol*, 18(9): 394–399.
20. R.A. Freitas Jr., 1999, *Nanomedicine, Volume I: Basic Capabilities*, Georgetown, Landes Bioscience.
21. P. Balasubramanian, S. Japa, 2003 « Nanosensing » *Stanford Biomedicine Quarterly*, p. 13.
22. Y. Xiao *et al.*, 2003 « Plugging into enzymes: Nanowiring of redox enzymes by a gold nanoparticle », *Science*, 21;299(5614):1877–1881.
23. G. Voskerician *et al.*, 2002 « Biocompatibility and biofouling of MEMS drug delivery devices », *Biomaterials*, 24:1959–1967.
24. K. Ishiyama, M. Sendoh, K. I. Arai, 2002, « Magnetic micromachines for medical applications » *J Magnetism Magnetic Materials*, 242–245(P1):41–46.
25. R. Weiss, 2003, « Genetic circuit building blocks for cellular computation, communications, and signal processing », *Natural Computing, an International Journal*, (2):47–84.

NOTES

Chapitre 3

1. D.M. Eisenberg *et al.*, 1998, « Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey » *JAMA*, 280(18):1569–75.
2. N.M. Bressler *et al.*, 2003 « Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11 » *Arch Ophthalmol*, 121(11):1621–1624.
3. L.D. Michael, M.J. Allen, 1993 « Nutritional Supplementation, Electrical Stimulation and Age-Related Macular Degeneration » *J Orthomol Med* 8:168–171.

Chapitre 4

1. A. Soper, 2002 « Water and ice » *Science*, 297:1288–1289). D. Klug, 2001 « Glassy water » *Science*, 294:2305–2306. P. Geissler *et al.*, 2001 « Autoionization in liquid water » *Science*, 291(5511):2121–2124. J. K. Gregory *et al.*, 1997 « The water dipole moment in water clusters », *Science*, 275:814–817. K. Liu *et al.*, 1996 « Water clusters » *Science*, 271:929–933.
2. M.S. Jhon, J.D. Andrade, 1973 « Water and hydrogels » *J Biomed Mater Res*, 7(6):509–522. J.D. Andrade *et al.*, 1973 « Water as a biomaterial » *Trans. Am Soc. Artif. Intern Organs*, 19:1–7.
3. S. Weinhouse, 1995 « The acetyl group in fatty acid metabolism » *FASEB J*, 9(9):820–821. L.R. Empey *et al.*, 1991 « Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats » *Can J Physiol Pharmacol*, 69(4):480–487.
4. J.S. Pringle, A.M. Jones, 2002 « Maximal lactate steady state, critical power and EMG during cycling », *Eur J Appl Physiol*, 88(3): 214–216. B.S. Dien *et al.*, 2002 « Fermentation of sugar mixtures using *Escherichia coli* catabolite repression mutants engineered for production of L-lactic acid », *J Ind Microbiol Biotechnol*, 29(5):221–227. H. Pitkanen *et al.*, 2002 « Serum amino acid responses to three different exercise sessions in male power athletes », *J Sports Med Phys Fitness*, 42(4):472–480.
5. S. Kimura *et al.*, 2003, « Enzymatic assay for determination of bicarbonate ion in plasma using urea amidolyase », *Clin Chim Acta*, 328(1–2):179–184. A. Vesela, J. Wilhelm, 2002, « The role of carbon dioxide in free radical reactions of the organism », *Physiol Res*. 2002;51(4):335–339. D.A. Bushinsky *et al.*, 2002 « Acute acidosis-induced alteration in bone bicarbonate and phosphate », *Am J Physiol Renal Physiol*, 283(5):F1091–1097.
6. T. Nakamura *et al.*, 2003 « Serum fatty acid levels, dietary style and coronary heart disease in three neighboring areas in Japan: the Kumihama study », *Br J Nutr*, 89(2):267–272. F. Perez-Ruiz *et al.*, 2002 « Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output », *Arthritis Rheum*, 47(6):610–613.
7. M. Nydahl *et al.*, 2003 « Achievement of dietary fatty acid intakes in long-term controlled intervention studies: approach and methodology », *Public Health Nutr*, 6(1):31–40. G.R. Hynes *et al.*, 2003, « Effects of dietary fat type and energy restriction on adipose tissue fatty acid composition and leptin production in rats » *J Lipid Res*, 44(5):893–901. S.F. Knutsen *et al.*, 2003 « Comparison of adipose tissue fatty acids with dietary fatty acids as measured by 24-hour recall and food frequency questionnaire in black and white adventists », *Ann Epidemiol*, 3(2):119–127.
8. B. Dincer *et al.*, 2002, « Scanning electron microscope study of the effects of soft drinks on etched and sealed enamel » *Am J Orthod Dentofacial Orthop*, 122(2):135–141. J. Fisher *et al.*, 2001, « Maternal milk consumption predicts the tradeoff between milk and soft drinks in young girls' diets » *J Nutr*, 131(2): 246–250. F. Garcia-Contreras *et al.*, 2000 « Cola beverage consumption induces bone mineralization reduction in ovariectomized rats » *Arch Med Res*, 31(4):360–365.
9. T. Ubuka, 2002, « Assay methods and biological roles of labile sulfur in animal tissues », *J Chromatogr B Analyt Technol Biomed Life Sci*, 5;781(1-2): 227–249.

SERONS-NOUS IMMORTELS ?

10. Voir note 8.
11. M. Maurer *et al.*, 2003 « Neutralization of Western diet inhibits bone resorption independently of K intake and reduces cortisol secretion in humans », *Am J Physiol Renal Physiol*, 284(1):F32–40. U.S. Barzel, 1995 « The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis » *J Bone Miner Res*, 10(10):1431–1436. L.A. Frassetto *et al.*, 2001, « Diet, evolution and aging – the pathophysiological effects of the post-agricultural inversion of the potassium-to-sodium and base-to-chloride ratios in the human diet », *Eur J Nutr*, 40(5):200–213.
12. J. Shuster *et al.*, 1992 « Soft drink consumption and urinary stone recurrence: a randomized prevention trial », *Journal Clinical Epidemiology*, 45(8):911–6. J. Shuster *et al.*, 1985, « Primary liquid intake and urinary stone disease », *Journal Chronic Disease*, 38(11):907–14. A. Rodgers, 1999 « Effect of cola consumption on urinary biochemical and physicochemical risk factors associated with calcium oxalate urolithiasis », *Urology Research*, 27(1):77–81. R. Siener, A. Hesse, 2003, « Fluid intake and epidemiology of urolithiasis », *Eur J Clin Nutr*, 57 Suppl 2:S47–51. T. Kessler, A. Hesse, 2000, « Cross-over study of the influence of bicarbonate-rich mineral water on urinary composition in comparison with sodium potassium citrate in healthy male subjects », *Br J Nutr*, 84(6): 865–87. G.C. Curhan, S.G. Curhan, 1994 « Dietary factors and kidney stone formation » *Compr Ther*, 20(9):485–9. P.M. Hall, 2002 « Preventing kidney stones: calcium restriction not warranted » *Cleve Clin J Med.*, 69(11): 885–888. B. Shekarriz, M.L. Stoller, 2002 « Uric acid nephrolithiasis: current concepts and controversies » *J Urol*, 168(4 Pt 1): 307–1314. S.T. Reddy *et al.*, 2002 « Effect of lowcarbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism », *Am J Kidney Dis*, 40(2): 265–274;N.A. Breslau *et al.*, 1988, « Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism », *J Clin Endocrinol Metab*, 66(1):140–146. F. Grases *et al.*, 1998 « Biopathological crystallization: a general view about the mechanisms of renal stone formation » *Adv Colloid Interface Sci*, 74:169–194. J.M. Aguado, J.M. Morales, 1993, « The pathogenesis and treatment of kidney stones », *N Engl J Med*, 11;328(6):444.
13. V. Radosavljevic, S. Jankovic, J. Marinkovic, M. Djokic, 2003, « Fluid intake and bladder cancer. A case control study » *Neoplasma*, 50(3): 234–8.
14. G.R. Fernando, R.M. Martha, R. Evangelina, 1999 « Consumption of soft drinks with phosphoric acid as a risk factor for the development of hypocalcemia in postmenopausal women », *Journal Clin Epidemiol*, 52(10):1007–10. D.E. Sellmeyer *et al.*, 2001, « A high ratio of dietary animal to vegetable protein increases the rate of bone loss and the risk of fracture in postmenopausal women », *Am J Clin Nutr*, 73(1): 118–122.
15. M. Bertoni *et al.*, 2002, « Effects of a bicarbonate-alkaline mineral water on gastric functions and functional dyspepsia: a preclinical and clinical study », *Pharmacol Res*, 46(6): 525–31.
16. C.L. Wabner, C.Y. Pak, 1993, « Effect of orange juice consumption on urinary stone risk factors » *Journal Urology*, 149(6):1405–8. R. Honow *et al.*, 2003, « Influence of grapefruit, orange, and apple juice consumption on urinary variables and risk of crystallization », *Br J Nutrition*, 90(2):295–300.
17. A. Ishchenko *et al.*, 2003, « Age-dependent increase of 8-oxoguanine-, hypoxanthine-, and uracil-DNA glycosylase activities in liver extracts from OXYS rats with inherited overgeneration of free radicals and Wistar rats », *Med Sci Monit*, 9(1):BR16–24. Y. Okatani *et al.*, 2003, « Acutely administered melatonin restores hepatic mitochondrial physiology in old mice », *Int J Biochem Cell Biol*, 35(3):367–375. J. Sastre, 2002, « Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver », *Cell Mol Biol*, 48(6):685–692. A. Anantharaju, 2002, « Aging Liver: A review », *Gerontology*, 48(6):343–353.

Chapitre 5

1. M. Bloomfield, L. Stephens, 1996, *Chemistry and the Living Organism*, New York: John Wiley and Sons. W. Tamborlane *et al.*, eds., 1997, *The Yale Guide to Children's Nutrition*, New Haven and London: Yale University Press.
2. E. Westman, 2002, « Is dietary carbohydrate essential for human nutrition? » *Am J Clin Nutr*, 75(5):951–953. A. E. Harper, « Defining the essentiality of nutrients », in M.D. Shils *et al.*, eds, 1993. *Modern Nutrition in Health and Disease*, 9th ed. Boston: William and Wilkins, pp. 3–10.
3. J.L. Vilotte, 2002 « Lowering the milk lactose content in vivo », *Reprod Nutr Dev*, 42:127–132). A. Ferguson, 1995, « Mechanisms in adverse reactions to food » *Allergy*, 50:32–38.
4. W. Willett, M. Stampfer, 2003, « Rebuilding the food pyramid » *Sci Amer*, 64–71. « The basics of good nutrition: Essential nutrients and their functions », in D. Tapley *et al.*, eds. 1995, *Columbia University College of Physicians and Surgeons Complete Home Medical Guide*, New York: Crown Publishers.
5. K. Milton, 1993, « Diet and primate evolution » *Sci Amer*, 86–93. « The basics of good nutrition: Essential nutrients and their functions », in D. Tapley *et al.*, eds. 1995, *Columbia University College of Physicians and Surgeons Complete Home Medical Guide*, New York: Crown Publishers.
6. K. Foster-Powell *et al.*, 2002, « International table of glycemic index and glycemic load values: 2002 » *Am J Clin Nutr*, 76(1): 5–56.
7. D. S. Ludwig *et al.*, 1999, « High glycemic index foods, overeating, and obesity », *Pediatrics*, 103:E26. D.S. Ludwig, 2001 « Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis » *Lancet*, 17;357:505–508.
8. F.S. Facchini *et al.*, 2001, « Insulin resistance as a predictor of age-related diseases » *J Clin Endocrinol Metab*, 86(8):3574–3578. J. Salmeron *et al.*, 1997, « Dietary fiber, glycemic load, and risk of noninsulin-dependent diabetes mellitus in women » *JAMA*, 12;277(6):472–477.
9. S.A. Bingham *et al.*, 2003, « Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study », *Lancet*, 3;361(9368):1496–1501. U. Peters *et al.*, 2003, « Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme », *Lancet*, 3;361(9368):1491–1495. S. Gråsten *et al.*, 2000, « Rye bread improves bowel function and decreases the concentrations of some compounds that are putative colon cancer risk markers in middle-aged women and men », *J Nutr*, 130:2215–2221.
10. N.M. Avena, B. G. Hoebel, 2003, « Amphetamine-sensitized rats show sugar-induced hyperactivity (cross-sensitization) and sugar hyperphagia », *Pharmacol Biochem Behav*, 74(3):635–639. C. Colantuoni *et al.*, 2002, « Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence », *Obes Res*, 10(6):478–488. C. Colantuoni *et al.*, 2001, « Excessive sugar intake alters binding to dopamine and muopioid receptors in the brain », *Neuroreport*, 12(16):3549–3552.
11. C.B. Ebbeling, D.S. Ludwig, 2001, « Treating obesity in youth: should dietary glycemic load be a consideration? » *Adv Pediatr*, 179–212. S.B. Roberts, 2000, « High-glycemic index foods, hunger, and obesity: is there a connection? » *Nutr Rev*, 58:163–169.
12. S. Higgenbotham *et al.*, 2004, « Dietary glycemic load and risk of colorectal cancer in the Women's Health Study », *J Natl Cancer Inst*, 4;96(3): 229–233.
13. K. Foster-Powell *et al.*, 2002, « International table of glycemic index and glycemic load values: 2002 », *Am J Clin Nutr* 76(1): 5–56.
14. S. Liu *et al.*, 2001, « Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women », *Am J Clin Nutr*, 73(3): 560–566.

SERONS-NOUS IMMORTELS ?

15. G.M. Reaven, 2003, « Age and glucose intolerance », *Diabetes Care*, 26:539–540. G.M. Reaven, 1998, « Insulin resistance and human disease: a short history », *Basic Clin Physiol Pharmacol* 9(2–4):387–406. J. Marx, 2002, « Unraveling the causes of diabetes », *Science*, 296(5568): 686–689.
16. M. Blüher *et al.*, 2003, « Extended longevity in mice lacking the insulin receptor in adipose tissue », *Science*, 24:299(5606):572–574. S.H. Golden *et al.*, 2002, « Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study » *Diabetes*, 51:3069–3076. F. Wollesen *et al.*, 2002, « Insulin resistance and atherosclerosis in diabetes mellitus » *Metabolism*, 51: 941–948.
17. J. Marx, 2002, « Unraveling the causes of diabetes », *Science*, 296(5568):686–689. R.K. Campbell, J.R. White, 2002, « Insulin therapy in type 2 diabetes », *J Am Pharm Assoc*, 42: 602–611. G.M. Reaven, 1999, « Insulin resistance: a chicken that has come to roost », *Ann NY Acad Sci*, 18:892: 45–57.
18. F. Abbasi *et al.*, 2002, « Relationship between obesity, insulin resistance, and coronary heart disease risk » *J Am Coll Cardiol*, 4:40(5):944–945. S. Liu, W.C. Willett, 2002, « Dietary glycemic load and atherothrombotic risk », *Curr Atheroscler Rep*, 4: 454–461. G.M. Reaven, 2000, « Diet and Syndrome X » *Curr Atheroscler Rep*, 2(6):503–507. S. Liu *et al.*, 2000, « A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in U.S. women », *Am J Clin Nutr*, 71(6):1455–1461. J. Yip *et al.*, 1998, « Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease », *J Clin Endocrinol Metab*, 83(8):2773–2776.
19. D.S. Michaud, 2002, « Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study », *J Natl Cancer Inst*, 94(17):1293–1300. L.S. Augustin *et al.* 2001, « Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study », *Ann Oncol* 12(11):1533–1538. E. Giovannucci, 2001, « Insulin, insulin-like growth factors and colon cancer: a review of the evidence », *J Nutr*, 131(11):3109S–20S.
20. W. Bell *et al.*, 2002, « Carcinogenicity of saccharin in laboratory animals and humans », *Int J Occup Environ Health*, 8:387–393. Y. Sasaki *et al.*, 2002, « The comet assay with 8 mouse organs: results with 39 currently used food additives », *Mutation Research*, 519(1–2): 103–119.
21. R.J. Wurtman, 1983, « Neurochemical changes following high-dose aspartame with dietary carbohydrates », *N Engl J Med*, 18;309(7):429–30. « Migraine provoked by aspartame », 1986, *N Engl J Med*, Aug 14;315(7):456. S.E. Moller, 1991, « Effect of aspartame and protein, administered in phenylalanine-equivalent doses, on plasma neutral amino acids, aspartate, insulin and glucose in man », *Pharmacol Toxicol*, 68(5):408–412.
22. D.L. Sprecher, G.L. Pearce, 2002, « Fiber-multivitamin combination therapy: a beneficial influence on low-density lipoprotein and homocysteine », *Metabolism*, 51(9):1166–1170. B. M. Davy *et al.*, 2002, « High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men », *Am J Clin Nutr*, 76(2):351–358. B.M. Davy, C.L. Melby, 2003, « The effect of fiber-rich carbohydrates on features of Syndrome X », *J Am Diet Assoc*, 103(1):86–96.
23. M. Hill, 2003, « Dietary fibre and colon cancer: where do we go from here? » *Proc Nutr Soc*, 62(1):63–65. American Dietetic Association and Dietitians of Canada, 2003, « Position of the American Dietetic Association and Dietitians of Canada: Vegetarian Diets », *Can J Diet Pract Res*, 64(2):62–81.
24. A. Mukherjee, J. Chakrabarti, 1997, « In vivo cytogenetic studies on mice exposed to acesulfame-K-a non-nutritive sweetener », *Food Chem Toxicol*, 35(12):1177–1179.
25. E. Koyama *et al.*, 2003, « In vitro metabolism of the glycosidic sweeteners, stevia mixture and enzymatically modified stevia in human intestinal microflora », *Food and Chem Toxicol*, 41(3):359–374. M. Matsui *et al.*, 1996, « Evaluation of the genotoxicity of stevioside and steviol using six in vitro and one in vivo mutagenicity assays », *Mutagenesis*, 11(6):573–579.

Chapitre 6

1. A.P. Simopoulos, 2002, « The importance of the ratio of omega-6/omega-3 essential fatty acids », *Biomed Pharmacother*, 56(8):365–379. M. Crawford *et al.* 2000, « Role of plant-derived omega-3 fatty acids in human nutrition », *Ann Nutr Metab*, 44(5–6):263–265.
2. F.B. Hu, M.J. Stampfer, 1999, « Nut consumption and risk of coronary heart disease: a review of epidemiologic evidence », *Curr Atheroscler Rep*, 1(3):204–209. J.L. Ellsworth *et al.*, 2001, « Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women in the Iowa Women's Health Study », *Nutr Metab Cardiovasc Dis*, 11(6):372–377.
3. J.T. Kuvin, R.H. Karas, 2003, « The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers », *Curr Opin Cardiol*, 18(4):295–300. T. Pischon *et al.* 2003, « Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women », *Circulation*, 108(2):155–160.
4. D. Bhatnagar, P.N. Durrington, 2003 « Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications », *Int J. Clin Pract* 57(4):305–314. F. Thies, 2003, « Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial » *Lancet*, 8;361(9356):477–485.
5. N. Fleshner *et al.*, 2004, « Dietary fat and prostate cancer », *J Urol*, 171(2 Pt 2):S19–24. L.N. Kolonel, A.M.Y. Nomura, R.V. Cooney, 1999, *J Natl Cancer Inst*, 91(5):414–428. L.M. Newcomer *et al.*, 2001, « The association of fatty acids with prostate cancer risk », *Prostate*, 1;47(4):262–268.
6. Y. Park, W.S. Harris, 2003, « Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance », *J Lipid Res*, 44(3):455–463. W.S. Harris, 1997, « n-3 fatty acids and serum lipoproteins: human studies », *Am J Clin Nutr*, 65(5 Suppl):1645S–1654S.
7. A.H. Lichtenstein, 2003, « Dietary fat and cardiovascular disease risk: quantity or quality? » *J Womens Health (Larchmt)*, 2(2):109–114.
8. H. Chen *et al.* 2003, « EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells », *J Mol Cell Cardiol*, 35(7):769–775. S.Renaud, D. Lanzmann-Petithory, 2002, « Dietary fats and coronary heart disease pathogenesis », *Curr Atheroscler Rep*, 4(6):419–424.
9. A. Nordoy *et al.*, 2001, « n-3 polyunsaturated fatty acids and cardiovascular diseases », *Lipids*, 36 Suppl:S127–129. K. Imaizumi *et al.*, 2000, « Role of dietary lipids in arteriosclerosis in experimental animals », *Biofactors*, 13(1-4):25–28. J.A. Conquer *et al.*, 1999, « Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects », *Thromb Res* 1;96(3):239–250.
10. P.C. Calder, 2002, « Dietary modification of inflammation with lipids », *Proc Nutr Soc* 61(3):345–358. P. Yang *et al.*, 2002, « Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells », *Anal Biochem* 1;308(1):168–177.
11. L.A. Sauer *et al.*, 2000, « Mechanism for the antitumor and anticachectic effects of n-3 fatty acids », *Cancer Res* 15;60(18):5289–5295.
12. P.M. Kris-Etherton *et al.*, 2002, « Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease », *Circulation*, 19;106(21):2747–2757.
13. M.E. Surette, 2003, « Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects », *Clin Ther*, 25(3):948–971. L.S. Harbige, 2003, « Fatty acids, the immune response, and autoimmunity: question of n-6 essentiality and the balance between n-6 and n-3 », *Lipids*, 38(4):323–341.

SERONS-NOUS IMMORTELS ?

14. D. Bagga *et al.*, 2003, « Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion », *Proc Natl Acad Sci USA*, 18;100(4):1751–1756.
15. T. van Vliet, M.B. Katan, 1990, « Lower ratio of n-3 to n-6 fatty acids in cultured than in wild fish » *Am J Clin Nutr*, 51(1):1–2. M.D. Eason *et al.*, 2002, « Preliminary examination of contaminant loadings in farmed salmon, wild salmon and commercial salmon feed », *Chemosphere*, 46(7):1053–1074.
16. M. Massaro *et al.*, 2002, « Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis », *Thromb Haemost*, 88(2):335–344. C.M. Williams, 2001, « Beneficial nutritional properties of olive oil: implications for postprandial lipoproteins and factor VII », *Nutr Metab Cardiovasc Dis* 11(4 Suppl):51–56.
17. T. Thosttrup *et al.*, 1994, « Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids », *Am J Clin Nutr*, 59(2):371–377.
18. F. Joffre *et al.*, 2001, « Kinetic parameters of hepatic oxidation of cyclic fatty acid monomers formed from linoleic and linolenic acid », *J Nutr Biochem*, 12(10):554–558. B. Potteau, 1976, « Influence of heated linseed oil on reproduction in the female rat and on the composition of hepatic lipids in young rats », *Ann Nutr Aliment*, 30(1):67–88.
19. J.K. Donnelly, D.S. Robinson, 1995, « Free radicals in food », *Free Radic Res*, 22(2):147–176.
20. A.H. Lichtenstein *et al.*, 1999, « Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels », *N Engl J Med*, 24;340(25):1933–1940.
21. N. de Roos *et al.*, 2001, « Consumption of a solid fat rich in lauric acid results in a more favorable serum lipid profile in healthy men and women than consumption of a solid fat rich in trans-fatty acids », *J Nutr*, 131(2):242–245.
22. A. Ammouche *et al.* 2002, « Effect of ingestion of thermally oxidized sunflower oil on the fatty acid composition and antioxidant enzyme of rat liver and brain in development », *Ann Nutr Metab*, 46(6):268–275.
23. S.M. Marcovina, M.L. Koschinsky, 2003, « Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside », *Curr Opin Lipidol*, 14(4):361–366. M. Koruk *et al.*, 2003, « Serum lipids, lipoproteins, and apolipoproteins levels in patients with nonalcoholic steatohepatitis », *J Clin Gastroenterol*, 37(2):177–182.
24. R. Rosmond, P. Björntorp, 1998, « The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men », *Int. J. Obes Relat Metab Disord*, 22(12):1184–1196.
25. S.M. Grundy *et al.*, 2002, « Diet composition and the metabolic syndrome: what is the optimal fat intake ? », *Am J Med*, 30;113 Suppl 9B:25S–29S.
26. F.D. Kelly *et al.*, 2001, « A stearic acid-rich diet improves thrombogenic and atherogenic risk factor profiles in healthy males », *Eur J Clin Nutr*, 55(2):88–96. C.M. Nieuwenhuys, G. Hornstra, 1998, « The effects of purified eicosapentanoic and docosahexanoic acids on arterial thrombosis tendency and platelet function in rats », *Biochem Biophys Acta*, 23;1390(3):313–322.
27. J.W. Ju, M.Y. Jung, 2003, « Formation of conjugated linoleic acids in soybean oil during hydrogenation with a nickel catalyst as affected by sulfur addition » ; *J Agric Food Chem*, 7;51(10):3144–3149. M.A. De Oliveira *et al.*, 2003, « Method development for the analysis of trans-fatty acids in hydrogenated oils by capillary electrophoresis », *Electrophoresis*, 24(10):1641–1647.
28. C. Thiele *et al.*, 2000, « Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles », *Nature Cell Biol*, 2:42–49.
29. L. Ellegård *et al.*, 2000, « Will recommended changes in fat and fibre intake affect cholesterol absorption and sterol excretion? », *Eur J Clin Nutr*, 54(4):306–313.

NOTES

30. I.S. Cowin, P.M. Emmett, 2001, « Associations between dietary intakes and blood cholesterol concentrations at 31 months », *Eur J Clin Nutr*, 55(1):39–49.
31. H. Lodish *et al.*, 2000, « Cell-to-cell signaling: hormones and receptors », *Molecular Cell Biology*, New York: W. H. Freeman and Company.
32. J. Scott, 1999, « Heart disease: good cholesterol news », *Nature*, 26;400:816–819.
33. A.E. Greene *et al.*, 2003, « Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies », *J Neurochem*, 86(3):529–537.
34. R.M. Anderson *et al.*, 1996, « Transmission dynamics and epidemiology of BSE in British cattle », *Nature*, 382:779–788.
35. J.X. Kang, 2004, « Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids », *Nature*, 5;427(6974):504.
36. F. Allen *et al.*, 2001, « Blue Gene: A vision for protein science using a petaflop supercomputer », *IBM Sys J*, 40(2):310–327.
37. C.L. Scott, 2003, « Diagnosis, prevention, and intervention for the metabolic syndrome », *Am J Cardiol*, 3;92(1A):35i–42i. F.B. Hu, W. C. Willett, 2002, « Optimal diets for prevention of coronary heart disease », *JAMA*, 27;288(20):2569–2578.
38. S. Moncada, A. Higgs, 1993, « The L-arginine-nitric-oxide pathway », *N Engl J Med*, 30;329(27):2002–2012.
39. A. L. Jenkins, 2002, « Depression of the glycemic index by high levels of α -glucan fiber in two functional foods tested in type 2 diabetes », *Eur J Clin Nutr*, 56(7):622–628.
40. J.W. Helge, 2002, « Prolonged adaptation to fat-rich diet and training; effects on body fat stores and insulin resistance in man », *Intl J Obesity*, 26(8): 1118–1124.
41. D.J. Jenkins *et al.*, 2000, « Dietary fibre, lente carbohydrates and the insulin-resistant diseases », *Br J Nutr*, 83(Suppl 1):S157–163.
42. E. Södergren *et al.*, 2001, « A diet containing rapeseed oil-based fats does not increase lipid peroxidation in humans when compared to a diet rich in saturated fatty acids », *Eur J Clin Nutr*, 55(11): 922–931.

Chapitre 7

1. D.A. Drossman *et al.*, 1993, « U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact » *Dig Dis Sci*, 38(9):1569–1580.
2. S.D. Krasinski *et al.*, 1986, « Fundic atrophic gastritis in an elderly population », *J Am Geriatr Soc*, 34(11):800–806. M. Inoue *et al.*, 2000, « Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence », *Cancer Lett*, 8;161(1):105–112. J. Wright, L. Lenard, 2001, *Why Stomach Acid Is Good for You*, New York: M. Evans & Co.
3. N.S. Scrimshaw, E.B. Murray, 1988, « The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance » *Am J Clin Nutr*, 48(Suppl 4):1079–1159. D.L. Swagerty Jr. *et al.*, 2002, « Lactose intolerance », *Am Fam Physician*, 1;65(9):1845–1850.
4. M. Morotomi, S. Kado, 2003 « Intestinal microflora and cancer prevention », *Gan To Kagaku Ryoho*, 30(6):741–747. F. Guarner, J.R. Malagelada, 2003, « Gut flora in health and disease », *Lancet*, 24;361(9371):1831.
5. L. Ferguson, 2002, « Meat consumption, cancer risk and population groups within New Zealand », *Mut Res*, 30;506–507:215–224. E.L. Matos, A. Brandani, 2002, « Review on meat consumption and cancer in South America », *Mut Res*, 30;506–507: 243–249.
6. S. Bingham *et al.*, 2003, « Dietary fibre in food and protection against colorectal cancer », *Lancet*, 3;361(9368):1496–1501. L. Ferguson, P. Harris, 2003, « The dietary fibre debate: more food for thought », *Lancet*, 3;361(9368):1487–1488.
7. P. D'Adamo, 1997, *Eat Right for Your Type*, New York: G. P. Putnam's & Sons.

SERONS-NOUS IMMORTELS ?

8. S. Barrie, 1999, « Comprehensive digestive stool analysis », in M.T. Murray, J.E. Pizzorno, *Textbook of Natural Medicine*, 2nd ed. New York: Churchill Livingstone, pp. 107–116.
9. J. Bland, 1999, *The 20-Day Rejuvenation Diet Program*, New York: McGraw-Hill.
10. F.R. Bornet, F. Brouns, « Immune-stimulating and gut health-promoting properties of short-chain fructo-oligosaccharides », *J Nutr Oct*, 60(10 Pt 1):326–334. C. Cherbut *et al.*, 2003, « The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats », *J Nutr*, 133(1):21–27.
11. A. Ferrar, 2003, « Metal poisoning », *An Sist Sanit Navar*, 26(Suppl 1):141–153. L. Patrick, 2003, « Toxic metals and antioxidants », *Altern Med Rev*, 8(2):106–128.
12. D. Karsenti *et al.*, 2001, « Small intestine bacterial overgrowth: six case reports and literature review », *Rev Med Interne*, 22(1):20–29. S.M. Riordan *et al.*, 2001, « Small intestinal bacterial overgrowth and the irritable bowel syndrome », *Am J Gastroenterol*, 96(8):2506–2508.
13. S.A. Dowsett, M.J. Kowolik, 2003, « Oral *Helicobacter pylori*: can we stomach it? », *Crit Rev Oral Biol Med*, 14(3):226–233.
14. S. Holt, ed., 2000, *Natural Ways to Digestive Health: Interfaces Between Conventional and Alternative Medicine*, New York: M. Evans and Company.
15. Y. Ringel *et al.*, 2001, « Irritable bowel syndrome » *Annu Rev Med*, 52:319–338. C.M. Porth, 1998, « Irritable bowel syndrome », in *Pathophysiology: Concepts of Altered Health States*, 5th ed. Philadelphia: Lippincott, pp. 729–730.
16. I. Kimber, R.J. Dearman, 2002, « Factors affecting the development of food allergy », *Proc Nutr Soc*, 61(4):435–439. E. Fernandez *et al.*, 2000, « Diet diversity and colorectal cancer », *Prev Med*, 31(1): 11–14.
17. M. Zimmerman, 2001, *Eat Your Colors: Maximize Your Health by Eating the Right Foods for Your Body Type*, New York: Henry Holt & Co.
18. K. Mukamal *et al.*, 2002, « Tea consumption and mortality after acute myocardial infarction », *Circulation*, 6;105:2476.
19. J.D. Lambert, C.S. Yang, 2003, « Cancer chemopreventative activity and bioavailability of tea and tea polyphenols » *Mutat Res*, 523–524:201–208. K. Maeda *et al.*, 2003, « Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier », *Atherosclerosis*, 166(1): 23–30.
20. A. Sierksma *et al.* 2002, « Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study », *Eur J Clin Nutr*, 56(11):1130–1136.

Chapitre 8

1. K.R. Fontaine *et al.*, 2003, « Years of life lost due to obesity », *JAMA*, 8;289(2):187–193.
2. T.E. Strandberg *et al.*, 2003, « Impact of midlife weight change on mortality and quality of life in old age », *Int J Obes*, 27(8):950–954. S.A. French *et al.*, 1997, « Weight variability and incident disease in older women: the Iowa Women's Health Study », *Int J Obes*, 21(3):217–223.
3. A.H. Mokdad *et al.*, 2001, « Prevalence of obesity, diabetes, and obesity-related health risk factors » *JAMA*, 1;289(1):76–79.
4. S. Kenchaiah *et al.*, 2002, « Obesity and the risk of heart failure » *N Engl J Med*, 1;347(5): 305–313. F.W. Ashley Jr., W. B. Kannell, 1974, « Relation of weight change to changes in atherogenic traits: the Framingham Study », *J Chronic Dis*, 27(3):103–114.
5. S. Orenstein, 2004, « The pill that will make you thin » *Business 2.0*, March, pp. 108–115.
6. G.K. Goodrick, J.P. Foreyt, 1991, « Why treatments for obesity don't last », *J Am Diet Assoc*, 91(10):1243–1247. F.M. Kramer *et al.*, 1989, « Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women », *Int J Obes*, 13(2):123–136.

NOTES

7. U.G. Kyle *et al.*, 2003, « Body composition interpretation: Contributions of the fat-free mass index and the body fat mass index » *Nutrition*, 19(7–8):597–604. D. Gallagher *et al.*, 2000, « Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index », *Am J Clin Nutr*, 72(3):694–701. B. Vizmanos, C. Martí-Henneberg, 2000, « Puberty begins with a characteristic subcutaneous body fat mass in each sex » *Eur J Clin Nutr*, 54(3):203–208.
8. S.P. Weisberg, A.W. Ferrante Jr., 2003, « Obesity is associated with macrophage accumulation in adipose tissue », *Journal of Clinical Investigation*, 112:1796–1808. K.E. Wellen, G.S. Hotamisligil, 2003, « Obesity-induced inflammatory changes in adipose tissue », *Journal of Clinical Investigation*, 112:1785–1788. H. Xu, H. Chen, 2003, « Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance », *Journal of Clinical Investigation*, 112:1821–1830. G.S. Hotamisligil *et al.*, 1994, « Tumor necrosis factor alpha inhibits signaling from the insulin receptor », *Proceedings of the National Academy of Sciences*, 91:4854–4858.
9. D.V. Schapira *et al.*, 1991, « Upper-body fat distribution and endometrial cancer risk », *JAMA*, 266(13):1808–1811.
10. N.K. Vikram *et al.*, 2003, « Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes », *Diabetes Nutr Metab*, 16(1):32–40. J.A. Lawati *et al.*, « Prevalence of the metabolic syndrome among omani adults » *Diabetes Care*, 26(6):1781–1785. K.M. Rexrode *et al.*, 2001, « Abdominal and total adiposity and risk of coronary heart disease in men », *Int J Obes*, 25(7):1047–1056.
11. A.E. Field *et al.*, 2001, « Relationship of a large weight loss to long-term weight change among young and middle-aged U.S. women », *Int J Obes*, 25(8):1113–1121. M.T. McGuire *et al.*, 1999, « The prevalence of weight loss maintenance among American adults », *Int J. Obes*, 23(22): 1314–1319.
12. D.E. Cummings *et al.*, 2002, « Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery », *N Engl J Med*, 346(21):1623–1630. D.E. Cummings, M. W. Schwartz, 2003, « Genetics and pathophysiology of human obesity » *Annu Rev Med*, 54:453–471.
13. R. Roubenoff *et al.*, 2000, « The effect of gender and body composition method on the apparent decline in lean mass-adjusted resting metabolic rate with age », *J Gerontol A Biol Sci Med Sci*, 55(12):M757–760. R. Andersen, 1999 « Exercise, an active lifestyle, and obesity », *Phys Sportmed*, 1;27(10).
14. B.B. Lowell, B.M. Spiegelman, 2000, « Towards a molecular understanding of adaptive thermogenesis », *Nature*, 404:652–660. C.R. Kahn, 2000, « Triclycerides and toggling the tummy », *Nature Genetics*, 25(1):6–7.
15. S.D. Hursting *et al.*, 2003, « Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans », *Annu Rev Med*, 54:131–152. V.E. Archer, 2003, « Does dietary sugar and fat influence longevity? » *Med Hypotheses*, 60(6):924–929.
16. M.A. Lane *et al.*, 2002, « Caloric restriction and aging in primates: relevance to humans and possible CR mimetics », *Microsc Res Tech*, 59(4):335–338.
17. B.P. Yu *et al.*, 1982, « Life span study of SPF Fischer 344 male rats fed ad libitum or restricted diets: longevity, growth, lean body mass, and disease », *J Gerontol*, 37(2):130–141.
18. Y. Minokoshi *et al.*, « AMP-Kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus », *Nature online*, March 17, 2004.
19. S.G. Bouret, S.J. Draper, R.B. Simerly, 2004, « Trophic Action of Leptin on Hypothalamic Neurons that Regulate Feeding » *Science*, April 2;304.
20. D. Kritchevsky, 1990, « Influence of caloric restriction and exercise on tumorigenesis in rats », *Proc Soc Exp Biol Med*, 193(1):35–38.
21. M. Blüher, B.B. Kahn, C.R. Kahn, 2003, « Extended longevity in mice lacking the insulin receptor in adipose tissue », *Science*, 299(5606):572–574. M. Blüher *et al.* 2002, « Adipose tissue selective

SERONS-NOUS IMMORTELS ?

- insulin receptor knockout protects against obesity and obesity-related glucose intolerance », *Dev Cell*, 3(1):25–38.
22. A. Cerami, 1985, « Hypothesis: glucose as a mediator of aging », *J Am Geriatr Soc*, 33(9):626–634. E.J. Masoro *et al.* « Evidence for the glycation hypothesis of aging from the food-restricted rodent model », *J Gerontol*, 44(1):B20–22.
 23. C.K. Ferrari, E.A. Torres, 2003, « Biochemical pharmacology of functional foods and prevention of chronic diseases of aging », *Biomed Pharmacother*, 57(5–6):251–260. D.T. Chiu, T.Z. Liu, 1997, « Free radical and oxidative damage in human blood cells », *J Biomed Sci*, 4(5):256–259.
 24. A. Koizumi *et al.*, 1987, « Influences of dietary restriction and age on liver enzyme activities and lipid peroxidation in mice », *J Nutr*, 117(2):361–367.
 25. R. Licastro, R. Weindruch, R.L. Walford, 1986, « Dietary restriction retards the age-related decline of DNA repair capacity in mouse splenocytes », in *Topics in Aging Research in Europe 9*. A. Facchini, J.J. Haaijman, G. Labo, eds, Rijswijk: EURAGE, pp. 53–61. R.J. Tice, R.B. Setlow, 1985, « DNA repair and replication in aging organisms and cells », in *Handbook of the Biology of Aging*. C.E. Finch and E.L. Schneider, eds. New York: Van Nostrand Reinhold, pp. 173–224.
 26. C. Kahn, 1990, « His theory is simple: eat less, live longer. A lot longer », *Longevity*, 61–66, esp. 64.
 27. S.A. Harrison *et al.*, 2003, « Orlistat in the treatment of NASH: a case series », *Am J Gastroenterol*, 98(4):926–930. M. Hanefeld, G. Sachse, 2002, « The effects of orlistat on body weight and glycemic control in overweight patients with type 2 diabetes: a randomized, placebo controlled trial », *Diabetes Obes Metab*, 4(6):415–423.
 28. M.D. Gades, J.S. Stern, 2003, « Chitosan supplementation and fecal fat excretion in men », *Obes Res*, 11(5): 683–688.

Chapitre 9

1. O. Dwyer, 2004, « U.S. government rejects WHO's attempts to improve diet », *BMJ*, 24;328 (7433): 185.
2. American Academy of Pediatrics Committee on School Health, 2004, « Soft drinks in schools », *Pediatrics*, 113(1 Pt 1):152–154.
3. F.G. Banting *et al.*, 1991, « Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922 », *CMAJ*, 15;145(10):1281–1286.
4. K.M. Flegel *et al.*, 2002, « Prevalence and trends in obesity among U.S. adults, 1999–2000 », *JAMA*, 9;288(14):1723–1727.
5. J.E. Manson, S.S. Bassuk, 2003, « Obesity in the United States: a fresh look at its high toll », *JAMA*, 8;289(2):229–230.
6. K.R. Fontaine *et al.*, 2003, « Years of life lost due to obesity », *JAMA*, 8;289(2):187–193.
7. E.S. Ford, W.H. Giles, W.H. Dietz, 2002, « Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey », *JAMA*, 16;287(3):356–359.
8. A. Agatston, 2003, *The South Beach Diet*. Emmaus, Pennsylvania: Rodale, p. 76.
9. G.M. Reaven, 1988, « Banting Lecture: Role of insulin resistance in human disease » *Diabetes*, 37:1595–1607.
10. G.M. Reaven *et al.*, 1993, « Insulin resistance and hyperinsulinemia in individuals with small dense LDL particles » *J Clin Invest*, 92:141–146.
11. L.C. Jones, A. Clark, 2001, « Beta cell neogenesis in type 2 diabetes mellitus », *Diabetes*, 50(Suppl 1):S186–187.
12. J.L. Wautier, P.J. Guillausseau, 2001, « Advanced glycation end products, their receptors and diabetic angiopathy », *Diabetes Metab*, 27(5 Pt 1):535–542.

NOTES

13. C. Chen *et al.*, 2003, *Nature Biotechnology*, 21:294–301.
14. J.M. Lehman *et al.*, 1995, « An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) », *J Biol Chem*, 270(22):12953–12956.
15. A.M.J., 2003, « Clinical islet transplant: current and future directions towards tolerance », *Immun Reviews*, 196:219–236.
16. « Growing human organs on the farm » *NewScientist*, 180(2426):4.
17. V.K. Ramiya, 2000, « Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells », *Ann NY Acad Science*, 958:59–68.
18. L. Knapp, 2003, « Diagnosis and medicine in a pill », *Wired News*, July 28, 2003.
19. S. Vasan, P. Foiles, H. Founds, 2003, « Therapeutic potential of breakers of advanced glycation end product-protein crosslinks », *Arch Biochem Biophys*, 419(1):89–96. D.A. Kass, 2003, « Getting better without AGE: new insights into the diabetic heart », *Circ Res*, 18:92(7):704–706.
20. D.A. Kass *et al.*, 2001, « Improved arterial compliance by a novel advanced glycation end-product crosslink breaker », *Circulation*, 104(13):1464–70.
21. C. Netzer, 2000, *The Complete Book of Food Counts*. New York: Random House.
22. J.P. Despres *et al.*, 1996, « Hyperinsulinemia as an independent risk factor for ischemic heart disease », *N Engl J Med*, 334(15):952–957.
23. G.S. Watson, S. Craft, 2003, « The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment », *CNS Drugs*, 17(1):27–45. P.J. Grant, 2003, « The genetics of atherothrombotic disorders: a clinician's view », *J Thromb Haemost*, 1(7):1381–1390. A.J. Scheen, F.H. Luyckx, 2003, « Nonalcoholic steatohepatitis and insulin resistance », *Acta Clin Belg*, 58(2): 81–91. E. W. Seely, C.G. Solomon, 2003, « Insulin resistance and its potential role in pregnancy-induced hypertension », *J Clin Endocrinol Metab*, 88(6):2393–2398.
24. F.S. Facchini *et al.*, 2001, « Insulin resistance as a predictor of age-related diseases », *J Clin Endocrinol Metab*, 86(8): 3574–3578.
25. R.A. Freitas Jr., 1999, *Nanomedicine, Volume 1: Basic Capabilities*. Austin, Texas: Landes Bioscience, pp. 93–122.
26. S. Jacob *et al.*, 1999, « Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial », *Free Radic Bio Med*, 27(3-4):309–314.
27. G. Boden *et al.*, 1996, « Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus », *Metabolism*, 45(9):1130–1135.
28. L.H. Storlien *et al.*, 1987, « Fish oil prevents insulin resistance induced by high-fat feeding in rats », *Science*, 237(4817):885–888.
29. R.B. Singh *et al.*, 1999, « Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease », *J Hum Hypertens*, 13:203–208.
30. M.F. McCarty, 1999, « High-dose biotin, an inducer of glucokinase expression may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes », *Med Hypotheses*, 52(5):401–406.
31. P.M. Piatti *et al.*, 2001, « Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients », *Diabetes Care*, 24(5):875–880.
32. C.W. Bates, 1995, « DHEA attenuates study-induced declines in insulin sensitivity in postmenopausal women », *Ann NY Acad Sci*, 774:291–293.
33. E.L. Barrett-Connor, 1995, « Testosterone and risk factors for cardiovascular disease in men », *Diab Metab*, 21:156–161.

Chapitre 11

1. J. Cohen, « Big-picture biotech » *MIT Technology Review* V, décembre 2003–janvier 2004.
2. *Ibid.*
3. R.J. Williams, 1998, *Biochemical Individuality: The Basis for the Genetotrophic Concept*. New York: Keats.
4. F.S. Collins *et al.*, 2003, « A vision for the future of genomics research » *Nature*, 24;422:835–847. M.E. Frazier *et al.*, 2003, « Realizing the potential of the genome revolution: the Genomes to Life Program », *Science*, 300:290. F.S. Collins, M. Morgan, A. Patrinos, « The Human Genome Project: lessons from large-scale biology », *Science*, 300:286. M. Ridley, 1999, *Genome: The Autobiography of a Species in 23 Chapters*. New York: Perennial.
5. D. Weatherall, 2003, « Evolving with the enemy », *NewScientist*, 802(2422):44.
6. E. Marshall, 1999, « Do-it-yourself gene watching », *Science*, 15;286(5439):444–447.
7. *Ibid.*
8. J. Rosamond, A. Allsop, 2000, « Harnessing the power of the genome in the search for new antibiotics », *Science*, 17;287(5460):1973–1976.
9. A. Dove, 2002, « Antisense and sensibility », *Nature Biotechnology*, 20:121–124.
10. J. Hahn, C.M. Lieber, 2004, « Direct Ultrasensitive Electrical Detection of DNA and DNA Sequence Variations Using Nanowire Nanosensors », *Nano Letters*, 4(1):51–54.
11. J.M. Lancaster, 1997, « BRCA 1 and 2—A Genetic Link to Familial Breast and Ovarian Cancer » *Medscape Women's Health*, 2(2):7.
12. J. Zhang *et al.*, 2003, « Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes », *Proc Natl Acad Sci USA*, 4;100(3):1116–1121.
13. P.P. Singh, M. Singh, S.S. Mastana, 2002, « Genetic variation of apolipoproteins in North Indians », *Hum Biol*, 74(5):673–682. X. Li, Y. Du, X. Huang, 2003, « Association of apolipoprotein E gene polymorphism with essential hypertension and its complications », *Clin Exp Med*, 2(4):175–179. M. Eto *et al.*, 1988, « Familial hypercholesterolemia and apolipoprotein E4 », *Atherosclerosis*, 72(2-3):123–128.
14. R.H. Myers *et al.*, 1996, « Apolipoprotein E epsilon4 association with dementia in a populationbased study: The Framingham study », *Neurology*, 46(3):673–677.
15. M.I. Kamboh, 1995, « Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease », *Hum Biol*, 67(2):195–215.
16. R.H. Myers *et al.*, 1996, « Apolipoprotein E epsilon4 association with dementia in a populationbased study: The Framingham study », *Neurology*, 46(3):673–677.
17. A.J. Slioter *et al.*, 1998, « Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study », *Arch Neurol*, 55(7):964–968.
18. H.K. Hamdi, C. Keney, 2003, « Age-Related Macular Degeneration: A New Viewpoint », *Frontiers in Bioscience*, 1;8:305–314.
19. W. Retz *et al.*, 1998, « Free radicals in Alzheimer's disease », *J Neural Transm Suppl*, 54:221–36.

Chapitre 12

1. P.M. Ridker *et al.*, 1998, « Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women », *Circulation*, 98:731–733.
2. R.N. Kalra, 2002, « Small vessel disease and Alzheimer's dementia: pathological considerations », *Cerebrovasc Dis*, 13(Suppl 2):48–52.
3. E.M. Castano *et al.* 1995, « Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E », *Biochem J*, 1;306(Pt 2):599–604.

NOTES

4. R.A. Floyd, 1999, « Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development », *Free Radic Biol Med*, 26(9–10):1346–1355.
5. W. Marz *et al.* 1996, « Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation », *Ann NY Acad Sci*, 17;777:276–280.
6. T.G. Ohm *et al.*, 1999, « Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions », *Acta Neuropathol (Berl)*, 98(3):273–280. D.S. Yang *et al.*, 1997, « Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma », *J Neurochem*, 68(2):721–725.
7. R.B. Pyles, 2001, « The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors », *Herpes*, 8(3):64–68. R.F. Itzhaki *et al.*, 1997, « Herpes simplex virus type 1 in brain and risk of Alzheimer's disease », *Lancet*, 25;349(9047):241–244.
8. C. Gorman, A. Park, 2004, « The fires within » *Time*, 23;163(8):41.
9. B.S. Reddy *et al.*, 1992, « Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds », *Carcinogenesis*, 13(6):1019–1023.
10. A. Akhmedkhanov *et al.*, 2002, « Aspirin and lung cancer in women », *Br J Cancer*, 1;87(1):49–53.
11. Y.Y. Fan, K.S. Ramos, R.S. Chapkin, 1997, « Dietary gamma-linolenic acid enhances mouse macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation », *J Nutr*, 127(9):1765–1771. U.N. Das *et al.*, 1989, « Prostaglandins can modify gamma-radiation and chemical induced cytotoxicity and genetic damage in vitro and in vivo », *Prostaglandins*, 38(6):689–716.
12. J.I. Kreisberg, P.Y. Patel, 1983, « The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells », *Prostaglandins Leukot Med*, 11(4):431–442.
13. T. Hishinuma, T. Yamasaki, M. Mizugaki, 1999, « Effects of long-term supplementation of eicosapentanoic and docosahexanoic acid on the 2-, 3-series of prostacyclin production by endothelial cells » *Prostaglandins Other Lipid Mediat*, 57:333–340. V.E. Kelley *et al.*, 1985, « A fish oil diet rich in eicosapentanoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice », *J Immunol*, 134(3):1914–1919.
14. M. Laimer *et al.*, 2002, « Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention », *Int J Obes Relat Metab Disord*, 26: 659–662. M. Visser, 2001, « Higher levels of inflammation in obese children », *Nutrition*, 17:480–481.
15. J.K. Kiecolt-Glaser *et al.*, 2003, « Chronic stress and age-related increases in the proinflammatory cytokine IL-6 », *Proc Natl Acad Sci USA*, 22;100(15):9090–9095.
16. H. Bucher *et al.*, 2002, « n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials », *Am J Med*, 112:298–304.
17. I.A. Brouwer *et al.*, 2003, « Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA », *Eur J Clin Nutr*, 57(10):1323–1330. I. Rosenberg, 2002, « Fish-food to calm the heart », *New Engl J Med*, 346(15):1102–1103.
18. S. Abou-Raya, A. Naeem, K.H. Abou-El, 2002, « Coronary artery disease and periodontal disease: is there a link? » *Angiology*, 53(2):141–148. P. Hujuel *et al.*, 2000, « Periodontal disease and coronary heart disease risk », *JAMA*, 20;284(11):1406–1410.
19. P.P. Zandi, J.C. Breitner, J.C. Anthony, 2002, « Is pharmacological prevention of Alzheimer's a realistic goal? » *Expert Opin Pharmacother*, 3(4):365–380. B.M. McLendon, G.G. Chen, P.M. Doraiswamy, 2000, « Current and future treatments for cognitive deficits in dementia », *Curr Psychiatry Rep*, 2(1): 20–23.

SERONS-NOUS IMMORTELS ?

20. W.F. Stewart *et al.* 1997, « Risk of Alzheimer's disease and duration of NSAID use », *Neurology*, 48(3):626–632.
21. P.S. Sanmuganathan *et al.*, 2001, « Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials », *Heart*, 85(3):265–271.
22. M. Wolfe, D. Lichtenstein, S. Gurkirpal, 1999, « Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs », *N Engl J Med*, 17;340(24):1888–1899.
23. F.E. Silverstein *et al.*, 2000, « Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial », *JAMA*, 284:1247–1255. C. Bombardier *et al.* for the VIGOR Study Group, 2000, « Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis », *N Engl J Med*, 343:1520–1528.
24. P. Libby, *op. cit.*, p. 55.
25. B. Lindahl *et al.*, 2000, « Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease », *N Engl J Med*, 19;343(16):1139–1147. D.J. Rader, 2000, « Inflammatory markers of coronary risk », *N Engl J Med*, 19;343(16):1179–1182. C.J. Packard *et al.*, 2000, « Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group », *N Engl J Med*, 19;343(16):1148–1155.
26. I. Kushner, 2001, « C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging », *Cleve Clin J Med*, 68(6):535–537.
27. N. Rifai and P.M. Ridker, 2001, « High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease » *Clin Chem*, 47(3):403–411. P.M. Ridker *et al.*, 2000, « C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women », *N Engl J Med*, 23;342(12):836–843.
28. N. Sueoka *et al.*, 2001, « A new function of green tea: prevention of lifestyle-related diseases », *Ann NY Acad Sci*, 928:274–280.

Chapitre 13

1. G.L. Booth, E.E. Wang, 2000, « Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care », *CMAJ*, 11;163(1):21–29.
2. M.R. Malinow *et al.*, 1999, « Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association », *Circulation*, 99:178–182.
3. J. Yokota *et al.*, 2003, « Genetic alterations responsible for metastatic phenotypes of lung cancer cells », *Clin Exp Metastasis*, 20(3):189–193. K.S. McCully, 1994, « Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism », *Ann Clin Lab Sci*, 24(1):27–59.
4. M. Iscan *et al.*, 2002, « The organochlorine pesticide residues and antioxidant enzyme activities in human breast tumors: is there any association? », *Breast Cancer Res Treat*, 72(2):173–182. C. Charlier, G. Plomteux, 2002, « Environmental chemical pollution and risk of human exposure: the role of organochlorine pesticides », *Ann Biol Clin (Paris)*, 60(1):37–46. M.S. Wolff, P.G. Toniolo, 1995, « Environmental organochlorine exposure as a potential etiologic factor in breast cancer », *Environ Health Perspect*, 103(Suppl 7):141–145.
5. K. Nilsson *et al.*, 1996, « Hyperhomocysteinaemia—a common finding in a psychogeriatric population », *Eur J Clin Invest*, 26(10):853–859.

NOTES

6. S.R. Maxwell, 2000, « Coronary artery disease—free radical damage, antioxidant protection and the role of homocysteine », *Basic Res Cardiol*, 95(Suppl 1):165–171.
7. W.P. Castelli, 1996, « Lipids, risk factors and ischaemic heart disease », *Atherosclerosis*, 124(Suppl):S1–9. S.P. McIlroy *et al.*, 2002, « Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland », *Stroke*, 33(10):2351–2356.
8. M.J. Stampfer *et al.*, 1992, « A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians » *JAMA*, 19;268(7):877–881.
9. R. Clarke *et al.*, 1998, « Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease », *Arch Neurol*, 55(11):1449–1455.
10. P. O'Callaghan *et al.*, 2002, « Smoking and plasma homocysteine », *Eur Heart J*, 23(20):1580–1586. S. Tonstad, P. Urdal, 2002, « Does short-term smoking cessation reduce plasma total homocysteine concentrations? », *Scand J Clin Lab Invest*, 62(4):279–284. I.M. Graham *et al.*, 1997, « Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project », *JAMA*, 11;277(22):1775–1781.
11. J.M. Ellis, K.S. McCully, 1995, « Prevention of myocardial infarction by vitamin B6 », *Res Commun Mol Pathol Pharmacol*, 89(2):208–220.
12. D.G. Savage *et al.* 1994, « Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies », *Am J Med*, 96(3):239–246.
13. D.J. DeRose *et al.*, 2000, « Vegan diet-based lifestyle program rapidly lowers homocysteine levels », *Prev Med*, 30:225–33.
14. L.L. Husemoen *et al.*, 2004, « Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype », *Eur J Clin Nutr*, Advance online publication March 31, 2004.
15. M.S. van der Gaag *et al.*, 2000, « Effect of consumption of red wine, spirits, and beer on serum homocysteine », *Lancet*, 29;355(9214):1522.
16. J.F. Toole *et al.*, 2004, « Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial », *JAMA*, 4;291(5):565–575.
17. Homocysteine Lowering Trialists' Collaboration, 2000, « Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials », *Indian Heart J*, 52(7 Suppl):S59–64.
18. I.M. Graham *et al.*, 1997, « Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project », *JAMA*, 11;277(22):1775–1781.
19. M.R. Malinow *et al.*, 1998, « Reduction of Plasma Homocyst(e)ine Levels by Breakfast Cereal Fortified with Folic Acid in Patients with Coronary Heart Disease », *N Engl J Med*, 338:1009–1015.
20. E. Arnesen *et al.*, 1995, « Serum total homocysteine and coronary heart disease », *Int J Epidemiol*, 24(4):704–709.
21. I.M. Graham *et al.*, 1997, *op cit.*
22. E.K. Amouzou *et al.*, 2004, « High prevalence of hyperhomocysteinemia related to folate deficiency and the 677C→T mutation of the gene encoding methylenetetrahydrofolate reductase in coastal West Africa », *Am J Clin Nutr*, 79(4):619–624.
23. L.D. Botto, Q. Yang, 2000, « 5,10-Methylenetetrahydrofolate reductase (MTHFR) Gene Variants and Congenital Anomalies », *Am J Epidemiol*, 151(9):862–877. W. Herrman *et al.*, « Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and the B-vitamins: a facet of nature-nurture interplay », *Clin Chem Lab Med*, 41(4):547–553. S.S. Kang *et al.*, 1991, « Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations », *Am J Hum Genet*, 48(3):546–551.

24. L.A. Kluijtmans *et al.*, 1996, « Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease », *Am J Hum Genet*, 58(1):35–41.
25. M. Goodman *et al.*, 2001, « Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia », *Cancer Epidemiol Biomarkers Prev*, 10(12):1275–1280.
26. S. Matsushita *et al.*, 1997, « The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population [letter] », *Am J Hum Genet*, 61:1459–1460.

Chapitre 14

1. T.J. Woodruff *et al.*, 1998, « Public health implications of 1990 air toxics concentrations across the United States », *Environ Health Perspect*, 106(5):245–251.
2. J.A. Varner *et al.*, 1998, « Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity », *Brain Res*, 16; 784(1–2):284–298.
3. A. Hoshi *et al.*, 2001, « Concentrations of trace elements in sweat during sauna bathing », *Tohoku J Exp Med*, 195(3):163–169.
4. B.C. Kross *et al.*, 1996, « Proportionate mortality study of golf course superintendents », *Am J Ind Med*, 29(5):501–506.
5. J.M. Dement *et al.*, 1998, « Proportionate mortality among union members employed at three Texas refineries », *Am J Ind Med*, 33(4):327–340.
6. B.A. Evanoff, P. Gustavsson, C. Hogstedt, 1993 « Mortality and incidence of cancer in a cohort of Swedish chimney sweeps: an extended follow up study », *Br J Ind Med*, 50(5):450–459.
7. K.S. Schafer, S.E. Kegley, 2002, « Persistent toxic chemicals in the U.S. food supply », *J Epidemiol Community Health*, 56(11):813–817.
8. H. Lai, N.P. Singh, 1996, « Single- and double-strand DNA breaks in rat brain cells after acute exposure to radiofrequency electromagnetic radiation », *Int J Radiat Biol*, 69(4):513–521.
9. D. Leszczynski *et al.*, 2002, « Non-thermal activation of the hsp27/p38MAPK stress pathway by mobile phone radiation in human endothelial cells: Molecular mechanism for cancer- and blood-brain barrier-related effects », *Differentiation*, 70(2–3):120–129.
10. R.O. Becker, 1990, *Cross Currents: The Promise of Electromedicine, the Perils of Electropollution*, New York: J.P. Tarcher.
11. *Ibid.*
12. S. Boseley, 2000, « Hands-Free Mobiles Increase Radiation Risk », *The Guardian*, 4 avril.
13. S. Overell, 2001, « Scientists Believe a Ferrite Choke Clipped to the Wire of a Hands-Free Set Could Dramatically Lower Radiation », *Financial Times*, 12 février.
14. B.A. Methe *et al.*, 2003, « Genome of *Geobacter sulfurreducens*: metal reduction in subsurface environments », *Science*, 12(302):1967–1969.
15. S. Duke, 2003, « Weeding with transgenes », *Trends in Biotechnology*, 21(5):192–195.
16. H.Y. Ha *et al.*, 2003, « Chronic restraint stress massively alters the expression of genes important for lipid metabolism and detoxification in liver », *Toxicol Lett*, (146):49–63.
17. A.D. de Grey, 2003, « An Engineer's Approach to the Development of Real Anti-Aging Medicine », *Sci SAGE KE*, 8:VP1. A.D. de Grey, 2002, « Bioremediation meets biomedicine: therapeutic translation of microbial catabolism to the lysosome », *Trends Biotechnol*, 20(11):452–455.
18. H.L. Weiner, D.J. Selkoe, 2002, « Inflammation and therapeutic vaccination in CNS diseases », *Nature*, 19–26;420(6917):879–884. H.L. Weiner *et al.*, 2000, « Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease », *Ann Neurol*, 48(4):567–579.

NOTES

19. D. Beyersmann, 2002, « Effects of carcinogenic metals on gene expression », *Toxicol Lett*, 28;127(1-3): 63–68.
20. P. Weihe *et al.*, 2002, « Neurobehavioral performance of Inuit children with increased prenatal exposure to methylmercury », *Int J Circumpolar Health*, 61(1):41–49.
21. S.A. Thompson *et al.*, 1998, « Alterations in immune parameters associated with low level methyl mercury exposure in mice », *Immunopharmacol Immunotoxicol* 20(2):299–314.
22. H. Huggins, 1993, *It's All in Your Head*, New York: Avery Penguin Putnam.
23. A. Szutowicz, 2001 « Aluminum, NO, and nerve growth factor neurotoxicity in cholinergic neurons, *J Neurosci Res*, 1;66(5):1009–1018.
24. N. Song *et al.*, 2001, « CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China », *Carcinogenesis*, 22(1):11–16.
25. H. Payami *et al.*, 2001, « Parkinson's disease, *CYP2D6* polymorphism, and age », *Neurology*, 22;56(10):1363–1370.
26. T. Konishi *et al.*, 2003, « The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American men », *Exp Mol Pathol*, 74(2):183–189.
27. H. Zheng *et al.* 2004, « Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism », *J Clin Pharmacol*, 44(2):135–140.
28. V. Fonte *et al.*, 2002, « Interaction of intracellular beta amyloid peptide with chaperone proteins », *Proc Natl Acad Sci USA*, 9;99(14):9439–9444.
29. P. Hammarstrom, F. Schneider, J.W. Kelly, 2001, « Trans-suppression of misfolding in an amyloid disease », *Science*, 28;293(5539):2459–2462.
30. P.M. Harrison *et al.*, 1999, « Thermodynamics of model prions and its implications for the problem of prion protein folding », *J Mol Biol*, 19;286(2): 593–606.

Chapitre 15

1. A. Michaels, K. Chatterjee, 2002, « Angioplasty versus bypass surgery for coronary artery disease », *Circulation*, 3;106(23):187–190.
2. E.L. Hannan *et al.*, 2003, « Do hospitals and surgeons with higher coronary artery bypass graft surgery volumes still have lower risk-adjusted mortality rates », *Circulation*, 19;108(7):795–801.
3. M.F. Newman *et al.*, 2001, « Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery » *N Engl J Med*, 8;344(6):395–402.
4. L.F. Wexler *et al.*, 2001, « Non-Q-wave myocardial infarction following thrombolytic therapy: a comparison of outcomes in patients randomized to invasive or conservative post-infarct assessment strategies in the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) Trial », *J Am Coll Cardiol*, 37(1):19–25. H.C. Bucher *et al.*, 2000, « Percutaneous transluminal angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomized controlled trials », *BMJ*, 8;321(7253):73–77. P. Peduzzi, A. Kamina, K. Detrie, 1999, « Twenty-two-year follow-up in the VA Cooperative Study of coronary artery bypass surgery for stable angina », *Am J Cardiol*, 15;83(2):301–304. G. A. Van Norman, K. Posner, 2000, « Coronary stenting or percutaneous transluminal coronary angioplasty before noncardiac surgery increases adverse events: the evidence is mounting », *J Am Coll Cardiol*, 36(7):2351–2352
5. C. Espinoza-Klein *et al.* 2000, « Ten-year outcome after coronary angioplasty in patients with single-vessel coronary artery disease and comparison with the results of the Coronary Artery Surgery Study (CASS) », *Am J Cardiol*, 1;85(3):321–326. M.M. Graham *et al.*, 2002, « Survival after coronary revascularization in the elderly », *Circulation*, 21;105(20):2378–2384. R. Conti. 1999, « Single-Vessel Disease: What is the Evidence Favoring Medical Versus Interventional Therapy », *Clin Cardiol*, 22,

SERONS-NOUS IMMORTELS ?

- 3-5. B.G. Brown *et al.*, 2001, « Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease », *N Engl J Med*, 29;345(22):1583–92.
6. L.L. Demer *et al.* 1994, « Mechanism of calcification in atherosclerosis », *Trends Cardiovasc Med*, 4:45–49. L.L. Demer, « Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation », *Circulation*, 1;83(6):2083–2093.
7. S. Grundy *et al.*, 1999, « Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations », *Circulation*, 100:1481–1492. N.C. Campbell *et al.* 1998, « Secondary prevention in coronary heart disease: a randomized trial of nurse-led clinics in primary care », *Heart*, 80(5):447–452. B.E. Sobel *et al.*, 2003, « Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial », *Circulation*, 4;107(4):636–642.
8. K.S. Prediman, 2003, « Mechanisms of plaque vulnerability and rupture », *J Am Coll Cardiol*, 19;41(4 Suppl 1):S15–S22. M. Takano *et al.*, 2001, « Mechanical and structural characteristics of vulnerable plaques analysis by coronary angiography and intravascular ultrasound », *J Am Coll Cardiol*, 38(1):99–104.
9. B.G. Brown *et al.*, 1986, « Incomplete Lysis of Thrombus in the Moderate Underlying Atherosclerotic Lesion during Intracoronary Infusion of Streptokinase for Acute Myocardial Infarction: Quantitative Angiographic Observations », *Circulation*, 73:653–661.
10. S.E. Nissen, J.C. Curley, 1991, « Application of intravascular ultrasound for detection and quantitation of coronary atherosclerosis », *Int J Card Imaging*, 6(3–4):165–177. P. Schoenhagen, E.S. McErlan, S.E. Nissen, 2000, « The vulnerable coronary plaque », *J Cardiovasc Nurs*, 15(1):1–12.
11. D.D. Waters, 2000, « Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial », *Can J Cardiol*, 16(Suppl A):11A–3A.
12. R.J. Aiello *et al.*, 2002, « Leukotriene B₄ receptor antagonism reduces monocytic foam cells in mice », *Arteriosclerosis Thromb Vasc Biology*, 22(3):361–363.
13. J.H. Dwyer *et al.*, 2004, « Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis », *N Engl J Med*, 1;350(1):29–37. I. Wickelgren, 2004, « Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation », *Science*, 13;303(5660):941.
14. J-C Tardif *et al.*, 2003, « Effects of AGI-1067 and probucol after percutaneous coronary interventions », *Circulation*, 107:552. G. Coté *et al.*, 1999, « Effects of probucol on vascular remodeling after coronary angioplasty », *Circulation*, 99:30–35.
15. Y. Hirakawa, H. Shimokawa, 2001, « Lipid-lowering drugs », *Nippon Yakurigaku Zasshi*, 1;118(6):389–395.
16. J.A. Blackie *et al.*, 2003, « The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A₂ », *Bioorg Med Chem Lett*, 13(6):1067–1070. D.P. Rotella, 2004, « SB-480848. GlaxoSmithKline », *Curr Opin Invest Drugs*, 5(3): 348–351.
17. J. Berliner *et al.*, 1995, « Atherosclerosis: basic mechanisms », *Circulation*, 1;91(9):2488–2496.
18. M.R. Naghavi *et al.*, 2001, « New developments in the detection of vulnerable plaque », *Curr Ather Rep*, 3(2):125–135. M.R. Naghavi *et al.*, 2001, « MRI detection of atherosclerotic vulnerable plaque using superparamagnetic iron oxide contrast media », *Am J Cardiol*, 19;88(2 Suppl 1):82.
19. K.J.O’Byrne, A.G. Dalglish, 2001, *Br J Cancer*, 85(4):473–483. L.E. Bautista, 2003, « Inflammation, endothelial dysfunction and the risk of high blood pressure: epidemiologic and biological evidence » *J Hum Hypertens*, 17(4):223–230.
20. D. Ponraj *et al.*, 1999, « The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion », *FEBS Lett*, 8;459(2):218–222. C.T. Sempos *et al.*, 2000, « Serum ferritin and death from all causes and cardiovascular disease: The NHANES II mortality study », *Ann Epidemiol*, 1;10(7):441–448).

NOTES

21. E. Falk *et al.* 1995, « Coronary plaque disruption », *Circulation*, 1;92(3):657–671. A.P. Schroeder, E. Falk, 1995, « Vulnerable and dangerous coronary plaques », *Atherosclerosis*, 118 (Suppl):S141–149.
22. A.C. van der Wal, A.E. Becker, 1999, « Atherosclerotic plaque rupture: pathologic basis of plaque stability and instability », *Cardiovasc Res*, 41:334–344. E. Falk *et al.*, 1995, « Coronary plaque disruption », *Circulation*, 1;92(3):657–671. E. Falk, 1992, « Why do plaques rupture? », *Circulation*, 86(Suppl III):III-30-III-42.
23. G. Chiesa, 2002, « Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks », *Circ Res*, 17;90(9):974–980. P.K. Shah *et al.* 2001, « Highdose recombinant apolipoprotein A-I milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice », *Circulation*, 26;103(25):3047–3050.
24. S.E. Nissen *et al.* 2003, « Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial », *JAMA*, 5;290(17):2292–2300.
25. M.E. Brousseau *et al.*, 2004, « Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol », *N Engl J Med*, 8;350(15):1505–1515.
26. W. Stanford *et al.* 1993, « Coronary artery calcification », *AJR Am J Roentgenol*, 161(6): 1139–1146.
27. N.D. Wong *et al.*, 1994, « Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women », *Am Heart J*, 127(2):422–430. A.S. Agatston *et al.* 1990, « Quantification of coronary artery calcium using ultrafast computed tomography », *J Am Coll Cardiol*, 15(4):827–832. A.S. Fiorino, 1998, « Electronbeam computed tomography, coronary artery calcium and evaluation of patients with coronary heart disease », *Ann Int Med*, 128:839–847.
28. C. Francis *et al.*, 2003, « Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement », *N Engl J Med*, 349:1703–1712. S.B. Olsson *et al.*, 2003, « Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial », *Lancet*, 362(9397):1691–1698.
29. A. Eisenberg, 2004, « An Ultrasound that Navigates Every Nook and Cranny », *New York Times*, 15 janvier.
30. D. Ornish, 1996, *Dr. Dean Ornish's Program for Reversing Heart Disease: The Only System Scientifically Proven to Reverse Heart Disease Without Drugs or Surgery*. New York: Ballantine Books.
31. G.H. Gibbons, V.J. Dzau, 1994, « The emerging concept of vascular remodeling », *N Engl J Med*, 330(20):1431–8.
32. G.A. Colditz *et al.*, 1988, « Cigarette smoking and risk of stroke in middle-aged women », *N Engl J Med*, 318(15):937–941. I. Kawachi *et al.* 1997, « A prospective study of passive smoking and coronary heart disease », *Circulation*, 95:2374–2379.
33. S. Kenchaiah *et al.*, 2002, « Obesity and the risk of heart failure », *N Engl J Med*, 347(5):305–313. P.W. Wilson *et al.*, 2002, « Overweight and obesity as determinants of cardiovascular risk: the Framingham experience », *Arch Intern Med*, 162(16):1867–1872. W.B. Kannel *et al.*, 1988, « Cardiac failure and sudden death in the Framingham Study », *Am Heart J*, 115(4):869–875.
34. T. Partonen *et al.*, 1999, « Association of low serum total cholesterol with major depression and suicide », *Br J Psych* 175:259–262. R. Manfredini *et al.*, 2000, « The association of low serum cholesterol with depression and suicidal behaviors: new hypotheses for the missing link », *J Int Med Res*, 28(6):247–257.
35. M.C. Bakogianni *et al.*, 2001, « Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in insulindependent diabetics with coronary artery disease », *J Diabetes Complications*, 15(5):265–269. B. Lamarche *et al.*, 1997, « Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study », *Arterioscler Thromb Vasc Biol*, 17(6):1098–1105.

SERONS-NOUS IMMORTELS ?

36. R.M. Krauss *et al.* 1994, « A prospective study of LDL particle diameter and risk of myocardial infarction », *Circulation*, 90:1–460. P.T. Williams *et al.*, 2003, « Smallest LDL particles are most strongly related to coronary disease progression in men », *Arterioscler Thromb Vasc Biol*, 23(2):314–321.
37. I. Gouni-Berthold, H.K. Berthold, 2002, Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent », *Am Heart J*. 143(2):356–365.
38. S. Nityanand *et al.* 1989, « Clinical trials with guggulipid: a new hypolipidaemic agent », *J Assoc Physicians India*, 37:323–328.
39. N.G. Stephens *et al.* 1996, « Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) », *Lancet*, 23;347(9004):781–786.
40. A. Gotto Jr., 2003, « Safety and statin therapy: reconsidering the risks and benefits », *Arch Intern Med*, 163:657–659. J. Tobert, 2003, « Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors », *Nature Rev Drug Discov*, 2:517–526.
41. B.R. Krause, R.S. Newton, 1995, « Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceridelowering in rats correlates with efficacy in LDL animal models », *Atherosclerosis*, 117(2):237–244.
42. P.M. Ridker *et al.* 1998, « Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women », *Circulation*, 98:731–733. P.M. Ridker *et al.*, 1997, « Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men », *N Engl J Med*, 336(14): 973–979. P.M. Ridker, 2001, « High-sensitivity C-reactive protein », *Circulation*, 103:1813–1818.
43. K. Miura *et al.*, 2001, « Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases and all causes in young adult men: The Chicago Heart Association Detection Project in Industry », *Arch Int Med*, 161(12):1501–1508.
44. J.P. Grégoire *et al.*, 2001, « Tolerability of antihypertensive drugs in a community-based setting », *Clin Ther*, 23(5):715–726. M. Weir, 2001, « Appropriate use of calcium antagonists in hypertension », *Hosp Pract*, 36(9):47–48, 53–55.)
45. S. Jacob *et al.*, 1998, « Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? », *Am J Hypertens*, 11(10):1258–1265. R. Fogari, 1998, « Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study », *Am J Hypertens*, 11(10):1244–1247.
46. T.Q. Miller *et al.*, « A meta-analytic review of research on hostility and physical health », *Psychol Bull*, 119(2):322–348. P.H. Black, 2002, « Stress and the inflammatory response: a review of neurogenic inflammation », *Brain Behav Immun*, 16(6):622–653.
47. J. Denollet, D. Brutsaert, 1998, « Personality, disease severity and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction », *Circulation*, 97:167–173. J. Denollet, 2000, « Type D personality. A potential risk factor defined », *J Psychosom Res*, 49(4): 255–266.
48. I. Wilcox *et al.*, 1998, « Syndrome Z': The interaction of sleep apnoea, vascular risk factors and heart disease », *Thorax*, 53(Suppl 3):S5–S28. J.E. Muller *et al.* 1997, « Mechanisms precipitating acute cardiac events », *Circulation*, 96:3233–3239.
49. D.H. Freedman, « The Virtual Heart », *Technology Review*, March 2004.
50. A. Mauriello *et al.*, 2000, « Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks », *Circulation*, 101:744. A. Maseri, V. Fuster, 2003, « Is there a vulnerable plaque? », *Circulation*, 107: 2068–2071.
51. P. Lotufo *et al.* 2000, « Male pattern baldness and coronary heart disease », *Arch Int Med*, 160(2): 165-71.

NOTES

52. M. Rasmussen *et al.*, 2001, « A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study », *Atherosclerosis*, 154(3):739–746.
53. « Antibodies to periodontal pathogens are associated with coronary heart disease », *Arterioscler Thromb Vasc Biol*, 23:1250. P. P. Hujoel *et al.*, 2000, « Periodontal disease and coronary heart disease risk », *JAMA*, 284(11):1406–1410.
54. A.D. Michaels *et al.*, 2002, « Left ventricular systolic unloading and augmentation of intracoronary pressure and Doppler flow during enhanced external counterpulsation », *Circulation*, 106:1237.
55. A.V. Chadwick, 2000, « Nanotechnology: solid progress in ion conduction », *Nature*, 408:925–926.
56. C.M. Winslow *et al.*, 1988, « The appropriateness of performing coronary artery bypass surgery », *JAMA*, 260(4): 505–509. R. Lange, D.L. Hillis, « Use and overuse of angiography and revascularization for acute coronary syndromes », *N Engl J Med*, 338(25):1838–1839.
57. S.G. Ellis *et al.*, 1992, « Randomized trial of late angioplasty versus conservative management for patients with residual stenosis after thrombolytic treatment of myocardial infarction », *Circulation*, 86(5):1400–1406. W.J. Rogers *et al.*, « Comparison of immediate invasive, delayed invasive and conservative strategies after tissue-type plasminogen activator », *Circulation*, 81(5):1457–1476. E. Schneider *et al.*, 2001, « Overuse of coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty », *Annals of Internal Medicine*, 135(5):S35. E. Schneider *et al.*, 2001, « Racial differences in cardiac revascularization rates: does 'overuse' explain higher rates among white patients ? », *Annals of Internal Medicine*, 135(5):328–337. W.E. Boden *et al.*, 1998, « Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy », *N Engl J Med*, 338:1785. E. Braunwald, 1988, « Evolution of the management of acute myocardial infarction : a 20th-century saga », *Lancet*, 352:1771–1774.
58. M.F. Newman *et al.* 2001, « Longitudinal assessment of neurocognitive function after coronaryartery bypass surgery », *N Engl J Med*, 344(6):395–402.
59. S. King, « Restenosis : the mouse that roared », *Circulation*, 108:248. P.A. Lemos *et al.*, « Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases », *Circulation*, 108(3):256–260.

Chapitre 16

1. J. Parsonnet *et al.*, 1994, « Helicobacter pylori infection and gastric lymphoma », *N Engl J Med*, 330(18):1267–1271. S.H. Landis *et al.*, 1999, « Cancer statistics, 1999 », *Ca-A Cancer J Clin*, 49(1):8–31. T. Parker-Pope, 2004, « Ten major advances you're likely to see in the coming year », *Wall Street Journal*, 26 janvier. Y. Yu *et al.* 2004, « Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins », *Nature Biotech*, 22: 313–320.
2. T.J. Key *et al.*, 2004, « Diet, nutrition and the prevention of cancer », *Public Health Nutr.* (1A): 87–200.
3. J.W. Gofman and E. O'Connor, 1999, *Radiation from Medical Procedures in the Pathogenesis of Cancer and Ischemic Heart Disease : Dose-Response Studies with Physicians per 100,000 Population*, San Francisco : CNR Books.
4. S.H. Woolf, 1994, « Public health perspective: the health policy implications of screening for prostate cancer », *J Urol*, 152(5 Pt 2):1685–1688.
5. L.A. Koutsky, 2002, « A controlled trial of a human papilloma virus type 16 vaccine », *N Engl J Med*, 347(21):1645–1651.
6. O.J. Finn, 2003, « Cancer vaccines: between the idea and the reality », *Nat Rev Immunol*, (8):630–641. R.C. Kennedy, M.H. Shearer, 2003, « A role for antibodies in tumor immunity », *Int Rev Immunol*, 22(2):141–172.

SERONS-NOUS IMMORTELS ?

7. J.K. Gohagan *et al.*, 2000, « The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status », *Control Clin Trials*, 21(6 Suppl): 251S–272S.
8. J. Illes *et al.*, 2003, « Self-referred whole-body CT imaging: current implications for health care consumers », *Radiology*, 228(2): 346–351.
9. G. Kolata, 2001, « Questions grow over usefulness of some routine cancer tests », *New York Times*, 30 décembre.
10. T. Boehm *et al.*, 1997, « Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance », *Nature*, 390:404–407.
11. J. Alam, 2003, « Apoptosis: target for novel drugs », *Trends in Biotechnology*, 21(11):479–483.
12. P.J. Pickhardt *et al.*, 2003, « Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults », *N Engl J Med*, 349:2191–2200. M.M. Morrin, J.T. LaMont, 2003, « Screening virtual colonoscopy—Ready for prime time? », *N Engl J Med*, 349:2261–2264.
13. P.B. Cotton *et al.*, 2004, « Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia », *JAMA*, 291(14): 1713–1719.
14. P. Lichtenstein *et al.*, 2002, « The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies », *J Intern Med*, 252(3):184–205. N.L. Pedersen *et al.*, 2002, « The Swedish Twin Registry in the third millennium », *Twin Res*, 5(5):427–432.
15. J.D. Hayes, R.C. Strange, 2000, « Glutathione S-transferase polymorphisms and their biological consequences », *Pharmacology*, 61(3):154–166.
16. C.A. Gonzalez *et al.*, 2002, « Genetic susceptibility and gastric cancer risk », *Int J Cancer*, 100(3):249–260.
17. T. Soucchi, 2000, « The p53 tumor suppressor gene: from molecular biology to clinical investigation » *Ann NY Acad Sci*, 910:121–137; 137–139.
18. C.N. Holick *et al.*, 2002, « Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study », *Am J Epidemiol*, 156(6):536–547.
19. C. La Vecchia *et al.*, 2001, « Nutrition and health: epidemiology of diet, cancer and cardiovascular disease in Italy », *Nutr Metab Cardiovasc Dis*, 11(4 Suppl):10–15.
20. A. Trichopoulou *et al.*, 2003, « Adherence to a Mediterranean diet and survival in a Greek population », *N Engl J Med*, 348(26):2599–2608.
21. S. Watanabe, S. Uesugi, Y. Kikuchi. 2002, « Isoflavones for prevention of cancer, cardiovascular diseases, gynecological problems and possible immune potentiation », *Biomed Pharmacother*, 56(6):302–312.
22. Y.C. Wang, U. Bachrach, 2002, « The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG) », *Amino Acids*, 22(2):131–143.
23. R.W. Owen *et al.*, 2000, « Olive-oil consumption and health: the possible role of antioxidants », *Lancet Oncol*, 1:107–112.
24. E. Giovannucci *et al.*, 2002, « Importance of lycopene and tomato products to prevent prostate cancer. A prospective study of tomato products, lycopene, and prostate cancer risk », *J Natl Cancer Inst*, 94(5):391–398.
25. O. Warburg, 1956 « On the origin of cancer cells », *Science*, 123(3191):309–314.
26. S. Higgenbotham *et al.*, 2004, « Dietary glycemic load and risk of colorectal cancer in the Women's Health Study », *J Natl Cancer Inst*, 96(3):229–233. S. Higgenbotham *et al.*, 2004, « Dietary glycemic load and breast cancer risk in the Women's Health Study », *Cancer Epidemiol Biomarkers Prev*, 13(1):65–70.

NOTES

27. D.S. Michaud *et al.*, 2002, « Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study », *J Natl Cancer Inst*, 94(17):1293–1300.
28. W.B. Grant, 2002, « An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation », *Cancer*, 94(6):1867–1875.
29. A.P. Albino *et al.*, 2000, « Cell cycle arrest and apoptosis of melanoma cells by docosahexaneic acid: association with decreased pRb phosphorylation », *Cancer Res*, 60(15):4139–4145.
30. L. Settimi *et al.*, 2001, « Cancer risk among male farmers: a multi-site case-control study », *Int J Occup Med Environ Health*, 14(4):339–347.
31. K.M. Flegal *et al.*, 2002, « Prevalence and trends in obesity among U.S. adults, 1999–2000 ». *JAMA*. 288: 1723–1727.
32. R.A. Freitas Jr., 2002, « The future of nanofabrication and molecular scale devices in nanomedicine », *Studies in Health Technology and Informatics*, 80:45–59.
33. X.H. Gao *et al.*, 2002, « Quantum-dot nanocrystals for ultrasensitive biological labeling and multicolor optical encoding », *Journal of Biomedical Optics*, 7(4):532–537.
34. E. Cameron, L. Pauling, 1992, *Cancer and Vitamin C: A Discussion of the Nature, Causes, Prevention, and Treatment of Cancer with Special Reference to the Value of Vitamin C*, Philadelphia: Camino Books.
35. Q.S. Zheng, R.L. Zheng, 2002, « Effects of ascorbic acid and sodium selenite on growth and redifferentiation in human hepatoma cells and its mechanisms », *Pharmazie*, 57(4):265–269.
36. A.J. Duffield-Lillico *et al.* 2002, « Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial », *Cancer Epidemiol Biomarkers Prev*, 11(7):630–639.
37. O. Portakal *et al.*, 2000, « Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients », *Clin Biochem*, 33(4):279–284.
38. S.P. Verma *et al.*, 1997, « Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides », *Biochem Biophys Res Comm*, 233:692–696.
39. R. Rashmi, T.R. Santhosh Kumar, D. Karunagaran, 2003, « Human colon cancer cells differ in their sensitivity to curcumin-induced apoptosis and heat shock protects them by inhibiting the release of apoptosis-inducing factor and caspases », *FEBS Lett*, 538(1-3):19–24. T. Kawamori *et al.*, 1999, « Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer », *Cancer Res*, 59:597–601.
40. M.R. McDevitt *et al.*, 2001, « Tumor Therapy with Targeted Atomic Nanogenerators », *Science*, 294(5546):1537–1540.
41. A. Panzer, M. Viljoen, 1997, « The validity of melatonin as an oncostatic agent », *J Pineal Res*, 22(4):184–202.
42. S. Cos, E.J. Sanchez-Barcelo, 2000, « Melatonin, experimental basis for a possible application in breast cancer prevention and treatment », *Histol Histopathol*, 15(2):637–647.
43. M. Eichholzer *et al.*, 2001, « Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence », *Swiss Med Wkly*, 131(37–38):539–549.
44. H. Tapiero *et al.*, 2002, « Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies », *Biomed Pharmacother*, 56(5):215–222.
45. J. Virtamo *et al.*, 2003, « Incidence of cancer and mortality following alpha-tocopherol and betacarotene supplementation: a postintervention follow-up », *JAMA*, 290(4):476–485.
46. M. Caraballoso *et al.*, 2003, « Drugs for preventing lung cancer in healthy people », *Cochrane Database Syst Rev*, (2):CD002141. A. Arora, C. A. Willhite, D.C. Liebler, 2001, « Interactions of beta-carotene and cigarette smoke in human bronchial epithelial cells », *Carcinogenesis*, 22(8):1173–1178.

Chapitre 18

1. J.L. Raymond *et al.*, 1996, « The cerebellum: a neuronal learning machine? » *Science*, 272:1126–1131. J.J. Kim, R.F. Thompson, 1997, « Cerebellar circuits and synaptic mechanisms involved in classical eyeblink conditioning », *Trends Neuroscience*, 20:188–191. J.F. Medina *et al.*, 2000, « Timing mechanisms in the cerebellum: testing predictions of a large-scale computer simulation », *Journal Neuroscience*, 20:5516–5525. D.V. Buonomano, M.D. Mauk, 1994, « Neural network model of the cerebellum: temporal discrimination and the timing of motor responses », *Neural Computation*, 6:38–55.
2. B. Fischl, 2000, « Measuring the thickness of the human cerebral cortex from magnetic resonance images », *Proc Natl Acad Sci USA*, 97(20):11050–11055.
3. D.H. Hubel, T.N. Wiesel, 1965, « Binocular interaction in striate cortex of kittens reared with artificial squint », *Journal of Neurophysiology*, 28(6):1041–1059.
4. M.A. Packer *et al.*, 2003, « Nitric oxide negatively regulates mammalian adult neurogenesis », *Proc Natl Acad Sci USA*, 100(16):9566–9571.
5. C. Lie Dieter *et al.*, « Neurogenesis in the Adult Brain: New Strategies for CNS Diseases », in *Annual Reviews of Pharmacology and Toxicology* (in press).
6. L. Spinney, 2004, « Tea strainer in the neck 'stops strokes' », *New Scientist*, 181(2432):12.
7. G. Stix, 2003, « Ultimate self-improvement », *Sci Amer*, 44.
8. P. Ross, 2003, « Mind readers », *Sci Amer*, 77.
9. C. Newton, « Meditation and the brain », *MIT Technology Review*, février 2004. T. Singer, 2002, « The Innovation Factor: Your Brain on Innovation », *Inc. Magazine*, Septembre.
10. R.E. Callaway, R. Yuste, (The Salk Institute for Biological Studies, Systems Neurobiology Laboratory), 2002, « Stimulating Neurons with Light », *Curr. Opin. Neurobiology*, 12(5):587.
11. B.L. Sabatini, K. Svoboda, 2000, « Analysis of calcium channels in single spines using optical fluctuation analysis », *Nature*, 408:589–593.
12. J.L. Etnier, D.M. Landers, 1995, « Brain Function and Exercise: Current Perspectives », *Sports Medicine*, 19(2):81–85.
13. G. Brumfiel, 2002, « Futurists predict body swaps for planet hops », *Nature*, 418:359. A. Abbott, 2002, « Brain implants show promise against obsessive disorder », *Nature*, 419:658. B. Nuttin *et al.*, 1999, « Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder », *Lancet*, 354(9189):1526.
14. R.S. Hong *et al.*, 2003, « Dynamic range enhancement for cochlear implants », *Otol Neurotol*, 24(4):590–595. R.S. Tyler *et al.* 2002, « Three-month results with bilateral cochlear implants », *Ear Hear*, 23(1 Suppl):80S–89S.
15. R.J. Jensen *et al.*, 2003, « Thresholds for activation of rabbit retinal ganglion cells with an ultrafine, extracellular microelectrode », *Invest Ophthalmol Vis Sci*, 44(8):3533–3543.
16. M. George, 2003, « Stimulating the brain », *Sci Amer*, 67–73. F.M. Mottagy *et al.*, 1999, « Facilitation of picture naming after repetitive transcranial magnetic stimulation » *Neurology*, 53:1806–1812.
17. E. Stockstad, 2001, « New hints into the biological basis of autism », *Science*, 294:34–37.
18. D.J. Gerber *et al.*, 2003, « Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit », *PNAS*, 100:8993–8998.
19. J.S. Rhodes *et al.*, 2003, « Exercise increases hippocampal neurogenesis to high levels but does not improve spatial learning in mice bred for increased voluntary wheel running », *Behav Neurosci*, 117(5):1006–1016.
20. B. Draganski *et al.*, 2004 « Neuroplasticity: Changes in grey matter induced by training » *Nature*, 427:311–312.

NOTES

21. D.F. Hulstsch et al. 1999. "Use it or lose it: engaged lifestyle as a buffer of cognitive decline in aging? », *Psychol Aging*, 14(2):245–263.
22. E.P. Noble, 2000, « Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review », *Eur Psychiatry*, 15(2):79–89.
23. F.H. Gage, 2003, « Brain: Repair yourself », *Sci Amer*, 46–53.
24. M.A. McDaneil, 2003, « Brain-specific nutrients: a memory cure? » *Nutrition*, (11–12):957–75.
25. J. Polich, 2001, « Cognitive effects of a ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory », *Hum Psychopharmacol*, 16(5):409–416.
26. P. Bönöczk et al., 2000, « Role of sodium channel inhibition in neuroprotection: effect of vinpocetine », *Brain Res Bull*, 53(3):245–254. S.A. Erdo et al. 1996, « Vincamine and vincanol are potent blockers of voltage-gated Na channels », *Eur J Pharmacol*, 314(1–2):69–73. R. Balestreri, L. Fontana, F. Astengo, 1987, « A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction », *J Am Geriatr Soc*, 35(5):425–430.
27. M. Furushiro et al., 1997, « Effects of administration of soybean lecithin transphosphatidylated phosphatidylserine on impaired learning of passive avoidance in mice », *Jpn J Pharmacol*, 75(4):447–450.
28. E.H. Sharman et al. 2002, « Reversal of biochemical and behavioral parameters of brain aging by melatonin and acetyl L-carnitine », *Brain Res*, 957(2):223–230.
29. R.W. Stackman et al., 2003, « Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic ginkgo biloba treatment », *Exp Neurol*, 184(1):510–520.
30. J.M. Bourre et al., 1991, « Essentiality of n-3 fatty acids for brain structure and function », *World Rev Nutr Diet*, 66:103–117.
31. D.S. Heron et al., 1980, « Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes », *Proc Natl Acad Sci*, 77:7463–7467.
32. A.P. Simopoulos, 2001, « Evolutionary aspects of diet and essential fatty acids », *World Rev Nutr Diet*, 88:18–27. A.P. Simopoulos, A. Leaf, N. Salem, 1999, « Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids », *J Am Coll Nutr*, 18:487–489.
33. S. Yehuda et al., 2002, « The role of polyunsaturated fatty acids in restoring the aging neuronal membrane », *Neurobiol Aging*, 23(5):843–853.
34. E. Nemets et al., 2002, « Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder », *Am J Psychiatry*, 159:477–479. L.B. Marangell et al., 2003, « A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaneic acid in the treatment of major depression », *Am J Psychiatry*, 160:996–998.
35. S.Y. Chung et al., 1995, « Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in dementia mice », *J Nutr*, 125(6):1484–1489.
36. S.L. Ladd et al., 1993, « Effect of phosphatidylcholine on explicit memory », *Clin Neuropharmacol*, 16(6):540–549.
37. F. Fagnani et al., 2004, « Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications », *Dement Geriatr Cogn Disord*, 17(1–2):5–13. K.R. Krishnan et al., 2003, « Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease », *Am J Psychiatry*, 160(11):2003–2011.

Chapitre 19

1. N. Carvalhaes-Neto et al., 2002, « Urinary free cortisol is similar in older and younger women », *Exp Aging Res*, 28(2):163–168. E. Beale et al., 2002, « Changes in serum cortisol with age in critically ill patients », *Gerontology*, 48(2):84–92.
2. R. Sapolsky, 1998, *Why Zebras Don't Get Ulcers*, New York: W. H. Freeman.

SERONS-NOUS IMMORTELS ?

3. D.S. Khalsa, C. Stauth, 1997, *Brain Longevity*, New York: Warner Books.
4. E. Ferrari *et al.* 2001, « Age-related changes of the adrenal secretory pattern: possible role in pathological brain aging », *Brain Res Rev*, 37(1–3):294–300. E. Ferrari *et al.*, 2001, « Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates », *Eur J Endocrinol*, 144(4):319–329.
5. M. Racchi, C. Balduzzi, E. Corsini, 2003, « Dehydroepiandrosterone (DHEA) and the aging brain: flipping a coin in the 'fountain of youth' », *CNS Drug Rev*, 9(1):21–40. M. Boudarene, J.J. Legros, 2002, « Study of the stress response: role of anxiety, cortisol and DHEAs », *Encephale*, 28(2):139–146.
6. S. Shibata, 2000, « A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice », *Yakugaku Zasshi*, 120(10):849–862.
7. B. Singh *et al.*, 2001, « Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of *Withania somnifera* Dun », *Phytother Res*, 15(4):311–318.
8. B. Sears, 1999, *The Anti-Aging Zone*, New York: HarperCollins, p. 138.
9. P. Zimmet, S. Baba, 1990, « Central obesity, glucose intolerance and other cardiovascular disease risk factors: an old syndrome rediscovered », *Diabetes Res Clin Pract*, 10(Suppl 1):S167–171.
10. J. Nandi *et al.*, 2002, « Central mechanisms involved with catabolism », *Curr Opin Clin Nutr Metab Care*, 5(4):407–418.
11. D.A. Lawlor, G. Smith, S. Ebrahim, 2003, « Life course influences on insulin resistance: findings from the British Women's Heart and Health Study », *Diabetes Care*, 26(1):97–103. J.P. Despres *et al.*, 1996, « Hyperinsulinemia as an independent risk factor for ischemic heart disease », *N Engl J Med*, 334(15):952–957.
12. W. Regelson, C. Colman, 1996, *The Super Hormone Promise*, New York: Simon and Schuster.
13. W. Leowattana, 2001, « DHEA(S): the fountain of youth », *J Med Assoc Thai*, 84(Suppl 2):S605–612.
14. J.A. Lemon, D.R. Boreham, C.D. Rollo, 2003, « A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes », *Exp Biol Med*, 228:800–810. R.N. Butler *et al.*, 2002, « Is there an anti-aging medicine? », *Journals of Gerontology Series A: Biol Sci Med Sci*, 57:B333–B338.
15. E. Barrett-Connor, K.T. Khaw, S.S. Yen, 1986, « A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease », *N Engl J Med*, 315(24):1519–1524.
16. R.H. Straub *et al.*, 2002, « Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor », *Eur J Endocrinol*, 146(3):365–374.
17. W. Regelson, 1985, « Vitamin A, dehydroepiandrosterone (DHEA) and 5' nucleotidase: regulatory factors in tumor growth », *Cancer Invest*, 3(4):407–409.
18. A.H. Young, P. Gallagher, R.J. Porter, 2002, « Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients », *Am J Psychiatry*, 159(7):1237–1239.
19. L. Hackbert, J. R. Heiman, 2002, « Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women », *J Women's Health Gen Based Med*, 11(2):155–162. R.F. Spark, 2002, « Dehydroepiandrosterone: a springboard hormone for female sexuality », *Fertil Steril*, 77 (Suppl 4): 19–25.
20. W. Leowattana, *op cit.*
21. D. Rudman *et al.*, 1990, « Effects of human growth hormone in men over 60 years old », *N Engl J Med*, 323(1):1–6.
22. A. Vermeulin, 2002, « Aging, hormones, body composition, metabolic effects », *World J Urol*, 20(1):23–27.

NOTES

23. R.D. Murray *et al.*, 2002, « Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome », *Clin Endocrinol (Oxf)*, 56(4):525–532.
24. A.M. Ahmad *et al.*, 2002, « Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency », *Clin Endocrinol (Oxf)*, 56(4):431–437.
25. J. Svensson *et al.*, 2002, « Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults », *J Clin Endocrinol Metab*, 87(5):2121–2127.
26. D.E. Cummings, G.R. Merriam, 1999, « Age-related changes in growth hormone secretion: should the somatopause be treated? », *Semin Reprod Endocrinol*, 17(4):311–325. Y. B. Sverrisdottir *et al.*, 2003, « The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults », *J Hypertens*, 21(10):1905–1914.
27. M.R. Blackman *et al.*, 2002, « Growth hormone and sex steroid administration in healthy aged women and men », *JAMA*, 288:2282–2292.
28. M. Shim, P. Cohen, 1999, « IGFs and human cancer: implications regarding the risk of growth hormone therapy », *Horm Res*, 51(Suppl 3):42–51.
29. A. Beentjes *et al.*, 2000, « One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults », *Clin Endocrinol (Oxf)*, 52(4):457–462. M. Letsch *et al.*, 2003, « Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers », *Proc Natl Acad Sci USA*, 100(3):1250–1255. M.H. Torosian, 1993, « Growth hormone and prostate cancer growth and metastasis in tumorbearing animals », *J Pediatr Endocrinol*, 6(1):93–97.
30. J.R. Stout, 2002, « Amino acids and growth hormone manipulation », *Nutrition*, 18(7–8):683–684. R. Savine, P.H. Sonksen, 1999, « Is the somatopause an indication for growth hormone replacement? », *J Endocrinol Invest*, 22(5 Suppl):142–149.
31. A.J. Morales *et al.*, 1998, « The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in ageadvanced men and women », *Clin Endocrinol (Oxf)*, 49(4):421–432.
32. D. Leger *et al.*, 2004, « Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy », *Am J Med*, 116:91–95.
33. E. Schernhammer *et al.*, 2003, « Night-shift work and risk of colorectal cancer in the Nurses' Health Study », *JNCI*, 95(11):825–828. Y. Touitou, 2001, « Human aging and melatonin. Clinical relevance », *Exp Gerontol*, 36(7):1083–1100. F. Fraschini *et al.*, 1998, « Melatonin involvement in immunity and cancer » *Biol Signals*, 7(1): 61–72.

Chapitre 20

1. M.J. Legato, 2002, *Eve's Rib: The New Science of Gender-Specific Medicine and How It Can Save Your Life*, New York: Harmony Books.
2. A. Vashisht *et al.*, 2001, « Prevalence of and satisfaction with complementary therapies and hormone replacement therapy in a specialist menopause clinic », *Climacteric*, 4(3):250–256. S.L. Nand *et al.*, 1998, « Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group », *Climacteric*, 1(3):211–218.
3. J.E. Manson, K.A. Martin, 2001, « Clinical practice. Postmenopausal hormone-replacement therapy », *N Engl J Med*, 345(1):34–40.
4. J.A. Cauley *et al.*, 2001, « Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS) », *Am J Med*, 110(6):442–450.
5. M.P. Warren *et al.*, 2003, « Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: A longitudinal study », *Fertil Steril*, 80:398–404.

SERONS-NOUS IMMORTELS ?

6. J.A. Cauley *et al.*, 2003, « Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial », *JAMA*, 290(13):1729–1738.
7. C.T. Owens, 2002, « Estrogen replacement therapy for Alzheimer disease in postmenopausal women », *Ann Pharmacother*, 36(7):1273–1276. K. Yaffe, 1998, « Estrogen therapy in postmenopausal women: effects on cognitive function and dementia », *JAMA*, 4;279(9):688–695.
8. G.A. Colditz *et al.*, 1995, « The use of estrogens and progestins and the risk of breast cancer in postmenopausal women », *N Engl J Med*, 332(24):1589–1593.
9. C. Rodriguez *et al.*, 1995, « Estrogen replacement therapy and fatal ovarian cancer », *Am J Epidemiol*, 141(9):828–835.
10. Writing Group for the Women's Health Initiative Investigators, 2002, « Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial », *JAMA*, 288:321–333.
11. A.L. Hersh, M.L. Stefanick, R.S. Stafford, 2004, « National use of postmenopausal hormone therapy: annual trends and response to recent evidence », *JAMA*, 291(1):47–53. J.S. Haas *et al.*, 2004, « Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results », *Ann Intern Med*, 140(3):184–188.
12. J.T. Hargrove *et al.*, 1989, « Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone », *Obstet Gynecol*, 73(4):606–612.
13. A. DuPont *et al.*, 1991, « Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women », *Maturitas*, 13(4): 297–311.
14. K.M. Prestwood *et al.*, 2000, « The effect of low dose micronized 17 β -estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double-blind, placebo-controlled study », *J Clin Endocrinol Metab*, 85(12):4462–4469. B. Ettinger *et al.*, 1992, « Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women », *Am J Obstet Gynecol*, 166(2): 479–88.
15. M.C. Snabes *et al.*, 1997, « Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: A randomized, double-blind, placebo-controlled crossover trial », *Obstet Gynecol*, 89:332–339. G.M.C. Rosano *et al.*, 1993, « Beneficial effect of oestrogen on exercise induced myocardial ischemia in women with coronary artery disease », *Lancet*, 342:133–136. C. Haines *et al.*, 1996, « Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled crossover study », *Arch Intern Med*, 156:886–872.
16. H.N. Hodis *et al.*, 2003, « Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women », *N Engl J Med*, 349(6):535–545.
17. E.N. Meilahn *et al.*, 1998, « Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up », *Br J Cancer*, 78(9):1250–1255.
18. V. Bisagno, R. Bowman, V. Luine, 2003, « Functional aspects of estrogen neuroprotection », *Endocrine*, 21(1):33–41. D.F. Swaab *et al.* 2003, « Sex differences in the hypothalamus in the different stages of human life », *Neurobiol Aging*, 24(Suppl 1):S1–S16, discussion, S17–S19.
19. A. Kamada *et al.*, 2004, « A new series of estrogen receptor modulators: effect of alkyl substituents on receptor-binding affinity », *Chem Pharm Bull (Tokyo)*, 52:79–88.
20. D. Yin *et al.*, 2003, « Pharmacodynamics of selective androgen receptor modulators », *J Pharmacol Exp Ther*, 304(3):1334–1340.
21. A. Vincent, L. A. Fitzpatrick, 2000, « Soy isoflavones: are they useful in menopause? *Mayo Clin Proc*, 75(11):1174–1184.
22. T. Horiuchi *et al.* 2000, « Effect of soy protein on bone metabolism in postmenopausal Japanese women », *Osteoporos Int*, 11(8): 721–724. Y. Somekawa *et al.*, 2001, « Soy intake related to menopausal

- sal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women », *Obstet Gynecol*, 97(1):109–115.
23. X. Xu *et al.*, 2000, « Soy consumption alters endogenous estrogen metabolism in postmenopausal women », *Cancer Epidemiol Biomarkers Prev*, 9:781–786. L.A. Fitzpatrick, 2003, « Soy isoflavones: hope or hype? », *Maturitas*, 44(Suppl 1):S21–29. T. Kishida *et al.*, 2000, « Effect of dietary soy isoflavone aglycones on the urinary 16 α -to-2-hydroxyestrone ratio in C3H/HeJ mice », *Nutr Cancer*, 38(2):209–214.
 24. F. Kronenberg, A. Fugh-Berman, 2002, « Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials », *Ann Intern Med*, 137(10):805–813.
 25. Y.H. Ju *et al.*, 2000, « Estrogenic effects of extracts from cabbage, fermented cabbage, and acidified brussels sprouts on growth and gene expression of estrogen-dependent human breast cancer (MCF-7) cells », *J Agricultural Food Chem*, 48:4628. G. Murillo, R.G. Mehta, 2001, « Cruciferous vegetables and cancer prevention », *Nutr Cancer*, 41(1–2):17–28. J.H. Fowke, C. Longcope, J.R. Hebert, 2000, « Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women », *Cancer Epidemiol Biomarkers Prev*, (8):773–779.
 26. M.S. Brignall, 2001, « Prevention and treatment of cancer with indole-3-carbinol », *Altern Med Rev*, (6):580–589.
 27. J.R. Lee, 1999, *What Your Doctor May Not Tell You About Premenopause*. New York: Warner Books.
 28. H.B. Leonetti *et al.*, 1999, « Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss », *Obstet Gynecol*, 94(2): 225–228.
 29. B.G. Wren *et al.*, 2003, « Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women », *Menopause*, 10(1):13–18.
 30. S. Haga *et al.*, 2001, « Overexpression of the p53 gene product in canine mammary tumors », *Oncol Rep*, 8(6):1215–1219. G.R. Sahu *et al.*, 2002, « Rearrangement of p53 gene with overexpressed p53 protein in primary cervical cancer », *Oncol Rep*, 9(2):433–437. V.K. Moudgil *et al.*, 2001, « Hormonal regulation of tumor suppressor proteins in breast cancer cells », *J Steroid Biochem Mol Biol*, 76(1–5):105–117.
 31. K.J. Chang *et al.*, 1995, « Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo », *Fertil Steril*, 63(4):785–791.
 32. S. Shantha *et al.*, 2002, « Natural vaginal progesterone is associated with minimal psychological side effects : a preliminary study », *J Women's Health Gend Based Med*, 10(10):991–997. S.Ferrero *et al.*, 2002, « Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study », *Minerva Gynecol*, 54(6):519–530.
 33. E. Darj *et al.*, 1993, « Liver metabolism during treatment with estradiol and natural progesterone », *Gynecol Endocrinol*, 7(2):111–114.
 34. R.D. Langer, 1999, « Micronized progesterone: a new therapeutic option », *Int J Fertil Women's Med*, 44(2):67–73.
 35. J.L. Shifren *et al.*, 2000, « Transdermal testosterone treatment in women with impaired sexual function after oophorectomy », *N Engl J Med*, 343(10):682–688.
 36. E. Wespes, C.C. Schulman, 2002, « Male andropause: myth, reality, and treatment », *Int J Impot Res*, 14(Suppl 1):S93–S98.
 37. J.P. Heaton, A. Morales, 2001, « Andropause—a multisystem disease », *Can J Urol*, 8(2):1213–1222.
 38. F. Debruyne *et al.*, 2002, « Comparison of a phytotherapeutic agent (Permixon) with an alphablocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study », *Eur Urol*, 41(5):497–507. G. Campault *et al.*, 1984, « A double-blind trial of an extract of the plant serenoa repens in benign prostatic hyperplasia », *Br. J. Clin. Pharm*, 18:461.

SERONS-NOUS IMMORTELS ?

39. G.S. Gerber, 2000, « Saw palmetto for the treatment of men with lower urinary tract symptoms », *J Urol*, 163(5):1408–1412.
40. L.B. Nieuwoudt *et al.*, 1990, « Correlation between the macromolecular effects of estradiol and catecholestradiols and the total prostatic catecholestradiol concentration », *Clin Physiol Biochem*, 8(5):231–237.
41. A.M. Nakhla *et al.*, 1994, « Estradiol Causes the Rapid Accumulation of cAMP in Human Prostate », *Proc Natl Acad Sci USA*, 91 (12):5402–5405.
42. B.T. Ashok *et al.*, 2001, « Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol », *Nutr Cancer*, 41(1–2):180–187. J.J. Michnovicz, H. Adlercreutz, H.L. Bradlow, 1997, « Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans », *J Natl Cancer Inst*, 21;89(10):718–723.
43. K.J. Auborn *et al.*, 2003, « Indole-3-carbinol is a negative regulator of estrogen », *J Nutr*, 133(7 Suppl):2470S–2475S.
44. H.J. Jeong *et al.*, 1999, « Inhibition of aromatase activity by flavonoids », *Arch Pharm Res*, 22(3):309–312.
45. P. Taxel *et al.*, 2001, « The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men », *J Clin Endocrinol Metab*, 86(6):2869–2874.
46. J.S. Bland, 2002, *Nutritional Endocrinology: Breakthrough Approaches for Improving Adrenal and Thyroid Function*, Gig Harbor, Washington: Metagenics Educational Programs, pp. 141–142.
47. A.T. Guay *et al.*, 2003, « Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? » *Int J Impot Res*, 15(3):156–165.
48. L. Gooren, 2003, « Androgen deficiency in the aging male: benefits and risks of androgen supplementation », *J Steroid Biochem Mol Biol*, 85(2–5):349–355. A. Morales, 2002, « Androgen replacement therapy and prostate safety », *Eur Urol*, 41(2):113–120.
49. J.E. Morley, 2003, « The need for a men's health initiative », *J Gerontol A Biol Sci Med Sci*, 58:614–617.

Chapitre 21

1. B.N. Ames, P. Wakimoto, 2002, « Are vitamin and mineral deficiencies a major cancer risk ? » *Nat Rev Cancer*, 2(9):694–704.
2. J.E. DaVanzo *et al.*, 2003, « A study of the cost effects of daily multivitamins for older adults », The Lewin Group Inc.
3. T.S. Church *et al.*, 2003, « Reduction of C-Reactive Protein Levels Through Use of a Multivitamin », *Am J Med*, 115(9):702–707.
4. D. Shintani, D. DellaPenna, 1998, « Elevating the Vitamin E Content of Plants Through Metabolic Engineering », *Science*, 282:5396.
5. I. Ajjawi, D. Shintani, 2004, « Engineered plants with elevated vitamin E: a nutraceutical success story » *Trends in Biotechnology*, 22(3):104–107.
6. S.M. Kitesa *et al.*, 2004, « Supplementation of grazing dairy cows with rumen-protected tuna oil enriches milk fat with n-3 fatty acids without affecting milk production or sensory characteristics », *Br J Nutr*, 91(2):271–278.
7. B. Demmig-Adams, W. Adams III, 2002, « Antioxidants in photosynthesis and human nutrition », *Science*, 298:2149–2153. I. Raskin *et al.*, 2002, « Plants and human health in the twenty-first century », *Trends in Biotechnology*, 20(12):522–531.
8. *Ibid.*, p. 2153.

NOTES

9. B.N. Ames, I. Elson-Schwab, E.A. Silver, 2002, « Highdose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased $K(m)$): relevance to genetic disease and polymorphisms », *Am J Clin Nutr*, 75(4):616–658.
10. *Ibid.*, p. 1.
11. W.C. Willett, M.J. Stampfer, 2001, « Clinical practice. What vitamins should I be taking, doctor? », *N Engl J Med*, 345(25):1819–1824. R.H. Fletcher, K.M. Fairfield, 2002, « Vitamins for chronic disease prevention in adults: clinical applications », *JAMA*, 287(23):3127–3129.
12. IOM (Institute of Medicine), 2000, « Dietary Reference Intakes. Applications in Dietary Assessment. A Report of the Subcommittee on Interpretation and Uses of Dietary Reference Intakes and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board », National Academy Press: Washington, D.C.
13. S. Lieberman, N. Bruning, 1997, *The Real Vitamin and Mineral Book*, Garden City Park, New York: Avery Publishing Group. R. Atkins, 1998, *Dr. Atkins' Vita-Nutrient Solution*. New York: Simon and Schuster.
14. R.P. Heaney, 2003, « Long-latency deficiency disease: insights from calcium and vitamin D », *Am J Clin Nutr*, 78(5):912–919.
15. R.P. Heaney *et al.*, 2003, « Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol », *Am J Clin Nutr*, 77(1):204–10.
16. G.A. Plotnikoff, J.M. Quigley, 2003, « Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain », *Mayo Clin Proc*, 78(12):1463–1470.
17. G.J. Fosmire, 1990, « Zinc toxicity », *Am J Clin Nutr*, 51(2):225–227.
18. H.R. Casdorph, M. Walker, 1995, *Toxic Metal Syndrome*, Garden City Park, New York: Avery Publishing, pp. 75–127.
19. O. Portakal *et al.*, 2000, « Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients », *Clin Biochem*, 33(4):279–284.
20. I.P. Hargreaves, 2003, « Ubiquinone: cholesterol's reclusive cousin », *Ann Clin Biochem*, 40(Pt 3):207–218. B. Sarter, 2002, « Coenzyme Q10 and cardiovascular disease: a review », *J Cardiovasc Nurs*, 16(4):9–20. S. Greenberg, W.H. Frishman, 1990, « Co-enzyme Q10: a new drug for cardiovascular disease », *J Clin Pharmacol*, 30(7):596–608.
21. D. Bagchi *et al.*, 2002, « Cellular protection with proanthocyanidins derived from grape seeds », *Ann NY Acad Sci*, 957:260–270.
22. *Ibid.*
23. S. Lamm, 1997, *Younger At Last*, New York: Pocket Books, pp. 132–150.
24. H. Moini, L. Packer, N.E. Saris, 2002, « Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid », *Toxicol Appl Pharmacol*, 182(1):84–90.
25. D. Konrad *et al.*, 2001, « The antihyperglycemic drug alpha-lipoic acid stimulated glucose uptake via both GLUT4 translocation and GLUT4 activation », *Diabetes*, 50:1464–1471. K. Yaworsky *et al.*, 2000, « Engagement of the insulin-sensitive pathway in the stimulation of the glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes », *Diabetologia*, 43(3):294–303. A. El Midaoui, J. de Champlain, 2002, « Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid », *Hypertension*, 39(2):303–307.
26. A.M. Wang *et al.*, 2000, « Use of carnosine as a natural anti-senescence drug for human beings », *Biochemistry (Mosc)*, 65(7):869–871. C. Brownson, A.R. Hipkiss, 2000, « Carnosine reacts with a glycosylated protein », *Free Radic Biol Med*, 15;28(10):1564–1570.

27. A. Sgambato *et al.*, 2001, « Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage », *Mutat Res*, 20;496(1-2):171-180. S. Bastianetto, W. H. Zheng, R. Quirion, 2000, « Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons », *Br J Pharmacol*, 131(4):711-720.
28. J.M. Humphries, F. Khachik, 2003, « Distribution of lutein, zeaxanthin, and related geometrical isomers in fruit, vegetables, wheat, and pasta products », *J Agric Food Chem*, 26;51(5):1322-1327. E.L. Snellen *et al.*, 2002, « Neovascular age-related macular degeneration and its relationship to antioxidant intake », *Acta Ophthalmol Scand*, 80(4):368-371.
29. J.A. Mares-Perlman *et al.*, 2001, « Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey », *Am J Epidemiol*, 153(5):424-432.
30. R.S. Lord *et al.*, 2002, « Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites », *Altern Med Rev*, 7(2):112-129.
31. M.S. Brignall, 2001, « Prevention and treatment of cancer with indole-3-carbinol », *Altern Med Rev*, 6(6):580-589.
32. E. Giovannucci *et al.*, 1995, « Intake of carotenoids and retinol in relation to risk of prostate cancer », *J Natl Cancer Inst*, 87(23):1767-1776.
33. J.K. Rossinow *et al.*, 2003, « Effects of lycopene and vitamin E on gamma-irradiated prostate cancer cells », *Int J Radiat Oncol Biol Phys*, 57(2 Suppl):S348-349. E. Giovannucci *et al.*, 2002, « Prospective study of tomato products, lycopene, and prostate cancer risk », *J Natl Cancer Inst*, 6;94(5):391-398.
34. T. Wilt, A. Ishani, R. MacDonald, 2002, « Serenoa repens for benign prostatic hyperplasia », *Cochrane Database Syst Rev*, (3):CD001423. F. Debruyne *et al.* 2002, « Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study », *Eur Urol*, 41(5):497-506.
35. S.A. Dillon *et al.*, 2002, « Dietary supplementation with aged garlic extract reduces plasma and urine concentrations of 8-iso-prostaglandin F(2 alpha) in smoking and nonsmoking men and women », *J Nutr*, 132(2):168-171. A. Mohamadi, S.T. Jarrell, 2000, « Effects of wild versus cultivated garlic on blood pressure and other parameters in hypertensive rats », *Heart Dis*, 2(1):3-9.
36. C. Borek, 2001, « Antioxidant health effects of aged garlic extract », *J Nutr*, 131(3s):1010S-5S.
37. E. Annagard, 1994, « Nitric Oxide: Mediator, Murderer, and Medicine », *Lancet*, 343:1199-1207.

Chapitre 22

1. J.M. McGinnis, W.H. Foege, 1993, « Actual causes of death in the United States », *JAMA*, 270(18):207-212.
2. S.N. Blair *et al.*, 1989, « Physical fitness and all-cause mortality », *JAMA*, 262:2395-2401.
3. C.D. Lee, S.N. Blair, A.S. Jackson, 1999, « Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men », *Am J Clin Nutr*, 69(3):373-380.
4. S.N. Blair *et al.*, 1996, « Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women », *JAMA*, 276(3):205-210.
5. I.M. Lee, 2003, « Physical activity in women: how much is good enough? » *JAMA*, 10;290(10):1377-1378.
6. M.J. Malloy, J.P. Kane, 2001, « A risk factor for atherosclerosis: triglyceride-rich lipoproteins », *Adv Intern Med*, 47:111-136. A.H. Liem, J.W. Jukema, D.J. van Veldhuisen, 2003, « Secondary prevention in coronary heart disease patients with low HDL: what options do we have? » *Int J Cardiol*, 90(1):15-21. P.A. Metcalf *et al.*, 2001, « Factors associated with changes in serum total cholesterol levels over 7 years in middleaged New Zealand men and women: a prospective study », *Nutr Metab Cardiovasc Dis*, 11(5):298-305.

NOTES

7. G.F. Fletcher *et al.*, 1996, « Statement on exercise: benefits and recommendations for physical activity programs for all Americans », *Circulation*, 94:857–862. D.H. Mahler, 1995, *American College of Sports Medicine Guidelines for Exercise Testing and Prescription*, Baltimore, Maryland: Williams & Wilkins, p. 373.
8. M. Hargrave *et al.*, 2003, « Subtalar pronation does not influence impact forces or rate of loading during a single-leg landing », *J Athletic Training*, 38(1):18–23.
9. W. van Mechelen, 1992, « Running injuries: a review of the epidemiological literature », *Sports Med*, 14(5):320–335.
10. A.H. Goldfarb, A.Z. Jamurtas, 1997, « Beta-endorphin response to exercise: an update », *Sports Med*, 24(1):8–16. D.V. Taylor *et al.*, 1994, « Acidosis stimulates beta-endorphin release during exercise », *J Appl Physiol*, 77(4):1913–1918.
11. M.L. Stefanick *et al.*, 1998, « Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol », *N Engl J Med*, 339(1):12–20. T.R. Thomas *et al.*, 2002, « Exercise training does not reduce hyperlipidemia in pigs fed a high-fat diet » *Metabolism*, 51(12):1587–1595.

Chapitre 23

1. H. Malmros, 1950, « The relation of nutrition to health: a statistical study of the effect of the wartime on arteriosclerosis, cardiosclerosis, tuberculosis, and diabetes », *Acta Medica Scandinavia*, 246(Suppl):141–149. A. Keys, 1975, « Coronary heart disease: the global picture », *Atherosclerosis*, 22:153–154. R.G. Wilkinson, 1996, *Unhealthy Societies: The Afflictions of Inequality*. London: Routledge.
2. M. Grubisic-Ilic *et al.*, 2002, « Epidemiological study of suicide in the Republic of Croatia », *Eur Psych*, 17(5):259–264. D.J. Somasundaram, S. Rajadurai, « War and suicide in northern Sri Lanka », *Acta Psychiatr Scand*, 91(1):1–4.
3. C.M. Stoney *et al.*, 2002, « Acute psychological stress reduces plasma triglyceride clearance », *Psychophysiology*, 39(1):80–85.
4. A.M. Tacon, 2003, « Meditation as a complementary therapy in cancer », *Fam Community Health*, 26(1):64–73. M.J. Kreitzer, M. Snyder, 2002, « Healing the heart: integrating complementary therapies and healing practices into the care of cardiovascular patients », *Prog Cardiovasc Nurs*, 17(2):73–80.
5. A. Elkin, 1999, *Stress Management for Dummies*, New York: Wiley Publishing, Inc. S.S. Nussey, S.A. Whitehead, eds., 2001, « Catecholamine synthesis and secretion », *Endocrinology: An Integrated Approach*, BIOS Scientific Publishers, Ltd. N. Schneiderman, « Behavior, Autonomic Function, and Animal Models of Cardiovascular Pathology », in T.M. Dembroski, T.H. Schmidt, G. Blümchen, eds., 1983, *Biobehavioral Bases of Coronary Heart Disease*, Basel, Switzerland: Karger, pp. 304–364, 317–322. R.M. Sapolsky, 1990, « Stress in the Wild », *Sci Amer*, 116–124. R. Williams, 1989, *The Trusting Heart*, New York: Times Books, pp. 75–82.
6. R. Mislin, 2003, « The defense system of fear: behavior and neurocircuitry », *Clin Neurophysiol*, 33(2):55–66.
7. I. Kawachi *et al.*, 1998, « Prospective study of a self-report Type A scale and risk of coronary heart disease », *Circulation*, 98:405. T.M. Dembroski *et al.*, 1989, « Components of hostility as predictors of sudden death and myocardial infarction in the Multiple Risk Factor Intervention Trial » *Psychosom Med*, 54(5):514–522. T. Hallman, 2001, « Psychosocial risk factors for coronary heart disease, their importance compared with other risk factors and gender differences in sensitivity », *J Cardiovasc Risk*, 8(1):39–49. E.R. Greenglass, J. Julkunen, 1991, « Cook-Medley hostility, anger, and the Type A behavior pattern in Finland », *Psychol Rep*, 68(3 Pt 2):1059–1066. Y. Gidron and K. Davidson, 1996, « Development and preliminary testing of a brief intervention for modifying CHD-predictive hostility

SERONS-NOUS IMMORTELS ?

- components », *J Behav Med*, 19(3):203–220. N. Ravaja, T. Kauppinen, L. Keltikangas-Jarvinen, 2000, « Relationships between hostility and physiological coronary heart disease risk factors in young adults: the moderating influence of depressive tendencies », *Psychol Med*, 30(2):381–393. G.E. Miller *et al.*, 2003, « Cynical hostility, depressive symptoms, and the expression of inflammatory risk markers for coronary heart disease », *J Behav Med*, 26(6):501–515. J.E. Gallacher *et al.*, 2003, « Is type A behavior really a trigger for coronary heart disease events? », *Psychosom Med*, 65(3):339–346.
8. R.B. Williams Jr., 1987, « Psychological factors in coronary artery disease: epidemiologic evidence », *Circulation*, 76(Suppl I):1117–1123.
 9. I. Kawachi *et al.* 1998, « Prospective study of a self-report Type A scale and risk of coronary heart disease » *Circulation*, 98(5):405. J.E. Muller *et al.*, 1997, « Mechanisms precipitating acute cardiac events », *Circulation*, 96(9):3233–3239.
 10. J.C. Barefoot *et al.*, 1989, « The Cook-Medley hostility scale: item content and ability to predict survival », *Psychosom Med*, 51(1):46–57.
 11. J.C. Barefoot *et al.*, 1983, « Hostility, CHD incidence, and total mortality: a twenty-five-year followup study of 255 physicians » *Psychosom Med*, 45(1):59–63.
 12. J.C. Barefoot *et al.*, 1987, « Suspiciousness, health and mortality: a follow-up study of five hundred older adults », *Psychosom Med*, 49(5):450–457.
 13. S. Segerstrom *et al.*, 1998, « Optimism is associated with mood, coping, and immune change in response to stress », *J Pers Soc Psych*, 74(6):1646–1655. M.F. Scheier, C.S. Carver, 1987, « Dispositional optimism and physical well-being: the influence of generalized outcome expectancies on health » *J Pers*, 55(2):169–210.
 14. S.E. Taylor *et al.*, 2000, « Behavioral responses to stress in females: tend-and-befriend, not fight-orflight » *Psych Rev*, 107(3):411–429.
 15. M. Friedman, D. Ulmer, 1984, *Treating Type A Behavior and Your Heart*. New York: Alfred A. Knopf, pp. 175–237.
 16. T.H. Holmes, R.H. Rahe, 1967, « The social readjustment rating scale » *J Psychosom Res*, 11(2):227–237.
 17. E.B. Rimm *et al.*, 1991, « Prospective study of alcohol consumption and risk of coronary heart disease in men », *Lancet*, 338:464–468.
 18. P. McMahon, 2001, « Cause coffees' produce a cup with an agenda », *USA Today*, 25 juillet.
 19. M.J. Klag *et al.* 2002, « Coffee intake and risk of hypertension » *Arch Int Med*, 162:657–662.
 20. M. El Yacoubi *et al.* 2000, « The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse isn't shared by selective A(2A) adenosine receptor antagonists », *Psychopharmacol (Berl)*, 148(2):153–163. J.P. Boulenger *et al.*, 1984, « Increased sensitivity to caffeine in patients with panic disorders » *Arch Gen Psych*, 41:1067–1071.
 21. T. Thiele *et al.*, 1998, « Ethanol consumption and resistance are inversely related to neuropeptide Y levels » *Nature*, 396:366–369. M. Cockerill, 1998, « Low levels of brain chemical drives mice to drink », *Br Med J* (317):1544B.
 22. S.B. Caine, G.F. Koob, 1993, « Modulation of cocaine self-administration in the rat through D-3 dopamine receptors », *Science*, 260:1814–1816. G.F. Koob *et al.*, 1994, « Corticotropin releasing factor, stress and behavior », *Seminars in the Neurosciences*, 6:221–229. P. Hyytia, G.F. Koob, 1995, « GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats », *European Journal of Pharmacology*, 283:151–159. G. Schulteis, A. Markou, M. Cole, G.F. Koob, 1995, « Decreased brain reward produced by ethanol withdrawal », *Proc Natl Acad Sci USA*, 92:5880–5884. G.F. Koob, 1996, « Hedonic valence, dopamine, and motivation », *Molecular Psychiatry*, 1:186–189. G.F. Koob, 1996, « Drug addiction: The yin and yang of hedonic homeostasis », *Neuron*, 16:893–896. M. Spina *et al.*, 1996, « Appetite-suppressing effects of urocortin, a CRF-related

NOTES

- neuropeptide », *Science*, 273:1561–1564. D.A. Finn, R. H. Purdy, G.F. Koob, « Animal models of anxiety and stress-induced behavior: effects of neuroactive steroids », in S.S. Smith, ed., 2004, *Neurosteroid Effects in the Central Nervous System: The Role of the GABA-A Receptor*, Boca Raton, Florida: CRC Press, pp. 317–338. P.J. Kenny, I. Polis, G.F. Koob, A. Markou, 2003, « Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats », *European Journal of Neuroscience*, 17:191–195. G.F. Koob, 2003, « Neuroadaptive mechanisms of addiction: studies on the extended amygdala » *European Neuropsychopharmacology*, 13:442–452. G.F. Koob, « Drug reward and addiction », in L.R. Squire, F. E. Bloom, S.K. McConnell, J.L. Roberts, N.C. Spitzer, M.J. Zigmond, eds., 2003, *Fundamental Neuroscience*, San Diego: Academic Press, pp. 1127–1143. G.F. Koob, A.J. Roberts, B.L. Kieffer, C.J. Heyser, S.N. Katner, R. Ciccocioppo, F. Weiss, « Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology », in M. Galanter, ed., 2003, *Research on Alcoholism Treatment* (series title: *Recent Developments in Alcoholism*, vol. 16). New York: Plenum Press, pp. 263–281. G.F. Koob, L. Pulvirenti, « Drug addiction and loss of control: focus on motivation in an allostatic perspective. » In M. Massotti and L. Pulvirenti, eds. 2003. *Neuroscience of Drug Addiction: Focus on Neural Plasticity* (series title: *Rapporti ISTISAN 03/7*), Rome: Istituto Superiore di Sanita, pp. 39–48.
23. T. Phillips *et al.*, 1998, « Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors », *Nature Neuroscience*, (1):610–615.
24. University of California, 1989, *Berkeley Wellness Letter* 5.7.
25. S. Higgins, J. Katz, 1998, *Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications*. New York: Academic Press. T. Madge, 2004, *White Mischief: A Cultural History of Cocaine*. New York: Thunder's Mouth Press. C. Reinerman, H.G. Levine, eds., 1997, *Crack in America: Demon Drugs and Social Justice*, Berkeley: University of California Press. S. Ali, ed., 2000, *The Neurochemistry of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines*, New York: New York Academy of Sciences. E.V. Nunes, J.S. Rosecan, « Human neurobiology of cocaine », in H.I. Spitz, J.S. Rosecan, eds., 1987, *Cocaine Abuse: New Directions in Treatment and Research*. New York: Brunner/Mazel Publishers, pp. 48–97. S. Shiffman, T.A. Wills, eds., 1985, *Coping and Substance Use*. San Diego: Academic Press, pp. 41–42.
26. A. Nehlig, S. Boyet, 2000, « Dose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence », *Brain Res*, 858(1):71–77. K. Kendler, C. Prescott, 1999, « Caffeine intake, tolerance, and withdrawal in women: a population-based twin study », *Am J Psych*, 156: 223-228.
27. K. Spiegel *et al.*, 1999, « Impact of sleep debt on metabolic and endocrine function », *Lancet*, 23:354(9188):1435–1439.
28. H. Benson *et al.*, 1974, « The relaxation response », *Psychiatry*, 37:37–46. H. Benson *et al.*, 1975, « The relaxation response: psychophysiologic aspects and clinical applications », *Int J Psych Med*, 6:87–98. H. Benson, 1993, *The Wellness Book: The Comprehensive Guide to Maintaining Health and Treating Stress-Related Illness and Timeless Healing*, New York: Scribner. B.H. Chang *et al.*, 2004, « Relaxation response for Veterans Affairs patients with congestive heart failure: results from a qualitative study within a clinical trial », *Prev Cardiol*, 7(2):64–70. R. Bonadonna, 2003, « Meditation's impact on chronic illness » *Holist Nurs Pract*, 17(6):309–319. T. Esch, G.L. Fricchione, G.B. Stefano, 2003, « The therapeutic use of the relaxation response in stress-related diseases » *Med Sci Monit*, 9(2):RA23–34. G.D. Jacobs, 2001, « Clinical applications of the relaxation response and mind-body interventions » *J Altern Complement Med*, 7(Suppl 1):S93–101. C.L. Mandle *et al.*, 1996, « The efficacy of relaxation response interventions with adult patients: a review of the literature », *J Cardiovasc Nurs*, 10(3):4–26.
29. H. Benson *et al.*, 1974, « Decreased blood pressure in borderline hypertensive subjects who practiced meditation », *J Chron Dis*, 27:163–89.

SERONS-NOUS IMMORTELS ?

30. C.N. Alexander *et al.*, 1989, « Transcendental meditation, mindfulness, and longevity: an experimental study with the elderly », *J Pers Soc Psych*, 57:950–964.
31. H. Benson, M.Z. Klipper, 2000, *The Relaxation Response*. New York: William Morrow, pp. 23–25, 68–74.
32. J. Kabat-Zinn, 1990, *Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness*, New York: Delacorte Press. J. Kabat-Zinn, 1995, *Wherever You Go, There You Are: Mindfulness Meditation in Everyday Life*, New York: Hyperion.
33. N.M. Shinopulos, J. Jacobson, 1999, « Relationship between health promotion lifestyle profiles and patient outcomes of biofeedback therapy for urinary incontinence », *Urol Nurs* 19(4):249–253. P.D. Shenefelt, 2003, « Biofeedback, cognitive-behavioral methods, and hypnosis in dermatology: Is it all in your mind? » *Dermatol Ther*, 16(2):114–122. D. Shapiro, R.S. Surwit, « Biofeedback », in O.F. Pomerleau, J.P. Brady, eds., *Behavioral Medicine: Theory and Practice*. Baltimore: Wilkins & Williams.